COMPOSITIONS AND METHODS FOR THE TREATMENT OF VprBP-RELATED CANCERS

ABSTRACT

This disclosure provides methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity. Also provided are methods of determining the effectiveness of the methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity, methods for detecting a cancer, and methods for screening potential agents that inhibit VprBP kinase activity.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 14/514,223, filed Oct. 14, 2014, now U.S. Pat. No. 9,234,018, which claims the benefit under 35 U.S.C. §119(e) to U.S. Provisional Application No. 61/891,220, filed Oct. 15, 2013, the content of each of which is hereby incorporated by reference in its entirety.

STATEMENT OF GOVERNMENT SUPPORT

This invention was made with government support under NIH Grant GM84209 awarded by the National Institutes of Health. Accordingly, the government has certain rights in the invention.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 3, 2014, is named 064189-7083_SL.txt and is 17,329 bytes in size.

TECHNICAL FIELD

This invention generally relates to the methods and compositions for treating cancer and inhibiting the growth of a cancer cell or a tumor.

BACKGROUND

Genomic DNA in human cells is hierarchically packaged by histones to form a highly repressive structure of chromatin. The basic unit of chromatin is the nucleosome, which consists of 147-bp of negatively supercoiled DNA wrapped a core histone octamer containing pairs of each of the four core histones, H2A, H2B, H3 and H4. The dynamic posttranslational modifications of histone N-terminal and C-terminal domains (called histone “tails”), which extend away from the nucleosome, govern the structural diversity of chromatin and the accessibility of DNA, thus representing an important molecular mechanism underlying regulation of gene expression. VprBP is a nuclear protein that can interact with HIV viral protein R and the Cullin 4-DDB 1 ubiquitin ligase complex. Its cellular function has been studied mainly with respect to its role in regulating Cullin 4 E3 ubiquitin ligase activity and cell cycle progression. However, subsequent studies, predominantly from Inventor's laboratory, have revealed that VprBP stably binds to promoter nucleosomes and that this association represses p53-mediated chromatin transcription (Mol Cell Biol 32, 783-796). The C-terminal region of VprBP has an ability to interact with H3 N-terminal tails protruding from nucleosomes and is critical for the observed functions of VprBP. Overexpression and mutations of VprBP have been detected in bladder/breast/prostate cancer cells supporting the idea that it possesses oncogenic properties.

SUMMARY

In one aspect, this technology provides methods and compositions for treating cancer by inhibiting VprBP kinase activity.

In another aspect, this technology provides methods and compositions for activating tumor suppression by inhibiting VprBP kinase activity.

In still another aspect, this technology provides methods and compositions for inhibiting H2AT120p by inhibiting VprBP kinase activity.

In some embodiments, the VprBP kinase activity is inhibited by an inhibitor of VprBP. In one aspect, the inhibitor comprises, or alternatively consists essentially of, or yet further consists of, QTARKSTGGKAPRKQLATKAARK (SEQ ID NO: 12) or comprises, or alternatively consists essentially of, or yet further consists of, a synthetic peptide comprising a HIV1 TAT sequence and the H3 N-terminal tail domain which corresponds to amino acids 5-27 (QTARKSTGGKAPRKQLATKAARK (human histone H3 N-terminal tail corresponding to amino acids 5-27)-RKKRRQRRR (HIV1 TAT sequence)) (SEQ ID NO: 11), and sequences having at least 80% amino acid sequence identity to each thereof and having the same or similar biological activity. Since the regulation of H2AT120 phosphorylation is important in the control of cell growth and the establishment and maintenance of gene silencing, the present invention should make it possible to detect and regulate VprBP dysfunction related to cancer development. In addition, the invention provides a method of reducing H2AT120 phosphorylation by using histone H3 tail peptides which block VprBP kinase activity and therefore reduce VprBP carcinogenic potential in cancer cells.

In some embodiments, the VprBP kinase activity is inhibited by RNA interference. In some embodiments, the RNAi comprises, or alternatively consists essentially of, or yet further consists of, one or more polynucleotide of the group VprBP shRNA1 (SEQ ID NO: 1: 5′-CGAGAAACTGAGTCAAATGAA-3′), VprBP shRNA2 (SEQ ID NO: 2: 5′-AATCACAGAGTATCTTAGA-3′) or Bub1 shRNA (SEQ ID NO: 3:5′-CGAGGTTAATCCAGCACGTAT-3′), or an equivalent of each thereof.

In some embodiments, the VprBP inhibitor is a small molecule inhibitor of VprBP, such as a compound of the formula:

or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof.

In still another aspect, this technology provides a method for treating or inhibiting cancer comprising administering to a patient in need thereof an effective amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof, or an RNAi, wherein the RNAi comprises, or alternatively consists essentially of, or yet further consists of, one or more polynucleotide of the group VprBP shRNA1 (SEQ ID NO: 1: 5′-CGAGAAACTGAGTCAAATGAA-3′), VprBP shRNA2 (SEQ ID NO: 2: 5′-AATCACAGAGTATCTTAGA-3′) Bub1 shRNA (SEQ ID NO: 3:5′-CGAGGTTAATCCAGCACGTAT-3′), or an equivalent of each thereof.

The compound, a salt of the compound, or a solvate of the compound or the salt thereof, RNAi or a composition containing one or more thereof, can be administered locally or systemically by any appropriate method, e.g., to the site of infection, topically, rectally, vaginally, ocularly, subcutaneous, intramuscularly, intraperitoneally, urethrally, intranasally, by inhalation or orally.

In still another aspect, this technology provides a method of detecting a VprBP-related cancer in a patient, comprising, or alternatively consisting essentially thereof, or yet further consisting of, determining the presence of VprBP in a sample of the patient, wherein the presence of VprBP is indicative of a cancer in the patient.

In some embodiments, an overexpression of VprBP is indicative of a cancer in the patient. In some embodiments, overexpression of VprBP means that the VprBP level in the sample is higher than the average or range of VprBP level of healthy individuals or individuals that do not have the cancer.

In some embodiments, the cancer or tumor is a solid tumor. In some embodiments, the cancer is bladder, breast or prostate cancer.

In still another aspect, this technology provides a method for determining the effectiveness of treating or monitoring the treatment a cancer, e.g., a VprBP-related cancer, by VprBP inhibition, comprising determining the gene expression of a gene selected from Tables 2 and 3 in a sample of the patient before VprBP inhibition and in a sample of the patient after VprBP inhibition, wherein activation of a gene selected from Table 2 or repression of a gene selected from Table 3 is indicative of effectiveness of VprBP inhibition in treating the cancer in the patient.

Activation of a gene refers to an increase in the expression of the gene in the presence of VprBP inhibition as compared with the expression of the gene in the absence of VprBP inhibition. In some embodiments, activation of a gene selected from Table 2 means that at least 0.5 or more, or alternatively at least 1, or more fold change in gene expression of a gene selected from Table 2 is found. In some embodiments, activation of a gene selected from Table 2 means that at least 1.5, or alternatively at least a 2 fold change in gene expression of a gene selected from Table 2 is found. In some embodiments, activation of a gene selected from Table 2 means that at least 3 fold change in gene expression of a gene selected from Table 2 is found. In some embodiments, activation of a gene selected from Table 2 means that at least 4 fold change in gene expression of a gene selected from Table 2 is found. In some embodiments, activation of a gene selected from Table 2 means that at least 5 fold change in gene expression of a gene selected from Table 2 is found. In some embodiments, the gene is one or more gene selected from LOC100008589, IL11, LOC100132564, RMRP, SCARNA18, LOC100008588, CD24 SCARNA11, LOC100133565, SLC22A18AS, Hs.543887, KIAA1644, MIR1978, NOV, SCARNA14, SCARNA8, C6orf48 and SCARNA16, or a combination thereof. In some embodiments, the gene is selected from LOC100008589, IL11, LOC100132564, RMRP, SCARNA18, LOC100008588, CD24 and SCARNA11, or a combination thereof.

Repression of a gene refers to a decrease in the expression of the gene in the presence of VprBP inhibition as compared with the expression of the gene in the absence of VprBP inhibition. In some embodiments, repression of a gene selected from Table 3 means that at least −0.5 fold, or at least −1.0, or alternatively at least a −1.5 fold change in gene expression of a gene selected from Table 3 is found. In some embodiments, repression of a gene selected from Table 3 means that at least −2 fold change in gene expression of a gene selected from Table 3 is found. In some embodiments, repression of a gene selected from Table 2 means that at least −3 fold change in gene expression of a gene selected from Table 3 is found. In some embodiments, repression of a gene selected from Table 3 means that at least −4 fold change in gene expression of a gene selected from Table 3 is found. In some embodiments, the gene is one or more gene selected from SNORD13, CYP24A1, RASL10A, CCL20, IGFBP3, LCN2, SRPX, SYTL2, ERLIN2, SPP1, OPLAH, TMEM145, HLA-DMA, PCK2, ANG, RNASE4, KIF1B, GALNTL1, ACCN2, MAP1LC3A, LAMP3, KISS1R, DDIT4L and CLYBL, or a combination thereof. In some embodiments, the gene is selected from SNORD13, CYP24A1, RASL10A, CCL20 and IGFBP3, or a combination thereof.

In some embodiments, the cancer comprise, or alternatively consists essentially of, or yet further consists of, a solid tumor. In some embodiments, the cancer is bladder, breast or prostate cancer.

In some embodiments, the sample is bladder, breast or prostate sample.

In some embodiments, the sample is a tissue sample comprising and/or suspected of comprising cancer or tumor cells.

In some embodiments, the sample is a blood or plasma sample.

In still another aspect, this technology provides a composition for treating cancer or for activation of tumor suppressor function in a cell in need thereof, comprising, or alternatively consisting essentially of, or yet further consisting of, a carrier and one or more of an effective amount of a compound of the formula:

or a pharmaceutically acceptable salt, or a solvate of the compound or the salt thereof or an equivalent of each thereof, or a polynucleotide comprising, or alternatively consisting essentially of, or yet further consisting of, VprBP shRNA1 (SEQ ID NO: 1: 5′-CGAGAAACTGAGTCAAATGAA-3′), VprBP shRNA2 (SEQ ID NO: 2: 5′-AATCACAGAGTATCTTAGA-3′) Bub1 shRNA (SEQ ID NO: 3:5′-CGAGGTTAATCCAGCACGTAT-3′), or an equivalent of each thereof.

In some embodiments, the effective amount of the compound is from about 1 mg/day to 10 g/day. In some embodiments, the effective amount of the compound is about 1 mg/day, about 10 mg/day, about 50 mg/day, about 100 mg/day, about 1 g/day, or about 10 g/day, or within any range between any two of these values (including endpoints). In some embodiments, the effective amount of the compound is from about 0.01 mg/kg to 100 mg/kg. In some embodiments, the effective amount of the compound is about 0.01 mg/kg, about 0.1 mg/kg, 1 mg/kg, about 10 mg/kg, about 50 mg/kg, or 100 mg/kg, or within any range between any two of these values (including endpoints).

In still another aspect, this technology provides a composition comprising, or alternatively consisting essentially of, or yet further consisting of, a carrier and a RNAi capable of inhibiting VprBP expression. In one aspect, the RNAi is present in the composition in an effective amount.

In some embodiments, the RNAi is selected from the group consisting of a polynucleotide comprising, or alternatively consisting essentially of, or yet further consisting of, a VprBP shRNA1 (SEQ ID NO: 1: 5′-CGAGAAACTGAGTCAAATGAA-3′), VprBP shRNA2 (SEQ ID NO: 2: 5′-AATCACAGAGTATCTTAGA-3′) and Bub1 shRNA (SEQ ID NO: 3:5′-CGAGGTTAATCCAGCACGTAT-3′), or an equivalent thereof.

In some embodiments, the effective amount of the compound is about 0.01 mg/kg, about 0.1 mg/kg, 1 mg/kg, about 10 mg/kg, about 50 mg/kg, or 100 mg/kg, or within any range between any two of these values (including endpoints).

In some embodiments, the carrier is a pharmaceutically acceptable carrier or an in situ device.

In some embodiments, the device is a catheter.

In still another aspect, this technology provides a screen to identify a potential therapeutic agent for inhibiting tumor growth or for tumor suppression, and in one aspect a VprBP-related tumor, comprising or alternatively consisting essentially of, or yet further consisting of, contacting a candidate agent with VprBP to initiate a kinase reaction, wherein the agent is a potential therapeutic agent if a reduction of kinase activity as compared to the kinase activity of VprBP in the absence of the agent is observed.

In some embodiments, the agent is a small molecule.

In some aspects of the above-noted embodiments, the patient is a non-human animal or a human patient. Non-human animals include, for example, simians, murines, such as, rats, mice, chinchilla, canine, equine, feline, leporids, such as rabbits, livestock, sport animals and pets.

In one aspect, the disclosure provides an isolated peptide, comprising, or alternatively consisting of, or yet further consisting essentially of, one or more of the sequence QTARKSTGGKAPRKQLATKAARK (SEQ ID NO: 12) or QTARKSTGGKAPRKQLATKAARK (human histone H3 N-terminal tail corresponding to amino acids 5-27)-RKKRRQRRR (HIV1 TAT sequence) (SEQ ID NO: 11), or an equivalent of each thereof, such as sequences having at least 80%, or alternatively at least 90% or alternatively at least 95% amino acid sequence identity and having the same or similar biological activity to competitively inhibit VprBP-medicated H2AT120 phosphorylation. In one aspect, the isolated peptide further comprises, or alternatively consists essentially of, or yet further consists of, a detectable label. Methods to recombinantly or chemically reproduce the isolated peptide are further provided herein.

Also provided herein is an isolated polynucleotide that encodes a peptide comprising or alternatively consisting of, or yet further consisting essentially of, the sequence QTARKSTGGKAPRKQLATKAARK (SEQ ID NO: 12) or QTARKSTGGKAPRKQLATKAARK (human histone H3 N-terminal tail corresponding to amino acids 5-27)-RKKRRQRRR (HIV1 TAT sequence) (SEQ ID NO: 11), or an equivalent of each thereof, such as sequences having at least 80%, or alternatively at least 90% or alternatively at least 95% amino acid sequence identity and having the same or similar biological activity to competitively inhibit VprBP-medicated H2AT120 phosphorylation. In one aspect, the polynucleotide hybridized under stringent conditions to the polynucleotide, or an equivalent thereof, or their compliments.

In still another aspect, this technology provides isolated, non-naturally occurring polynucleotide encoding VprBP or the polypeptides as disclosed herein, or a polynucleic acid which has at least 80%, 85%, 90% or 95% of sequence identity to a polynucleic acid encoding VprBP, or a fragment thereof. In one aspect, the non-naturally occurring polynucleotide comprises a cDNA or an isolated naturally occurring polynucleotide having attached thereto a non-naturally occurring element, such as a linker, a label or a non-naturally occurring polynucleotide.

In some embodiments, the cDNA is a cDNA of a polynucleic acid having a sequence encoding a polypeptide sequence comprising, or alternatively consisting essentially of, or yet further consisting of, a polynucleotide of the sequence: Q-PLRTYSTGLLGGAMENQDI (SEQ ID NO: 4), EVALRQENKRPSPRKLS (SEQ ID NO: 5), or both, or an equivalent of each thereof.

In some embodiments, the cDNA is a cDNA of a polynucleic acid comprising a sequence encoding a polypeptide sequence comprising, or alternatively consisting essentially of, or yet further consisting of, DPDRMFVELSNSSWSEMSPWVIGTNYTLYPMTPAIEQRL (SEQ ID NO: 6), or an equivalent thereof.

In some embodiments, the cDNA is a cDNA of a polynucleic acid having a sequence encoding a polypeptide sequence comprising, or alternatively consisting essentially of, or yet further consisting of, YIDLKQTNDVL (SEQ ID NO: 7), FATEFV (SEQ ID NO: 8), KLLEIPRPS (SEQ ID NO: 9), or QDAMERVCM (SEQ ID NO: 10), or two or more of SEQ ID NO: 7 to SEQ ID NO: 10, or an equivalent of each thereof.

In some embodiments, the cDNA is a cDNA of a polynucleic acid having a sequence encoding a polypeptide sequence comprising, or alternatively consisting essentially of, or yet further consisting of, two or more of SEQ ID NO: 4 to SEQ ID NO: 10, or an equivalent of each thereof. In some embodiments, the cDNA is a cDNA of a polynucleic acid having a sequence encoding a polypeptide sequence comprising, or alternatively consisting essentially of, or yet further consisting of, all of SEQ ID NO: 4 to SEQ ID NO: 10, or an equivalent of each thereof.

Polynucleotides (such as cDNA or RNAi) as used herein can be combined with a vector or contained within a cell of delivery or expression. Any art recognized method for therapeutic delivery or expression of such are intended within the scope of this disclosure.

Kits are further provided which contain the compositions described herein and instructions for intended use.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A-1G show VprBP phosphorylates histone H2A at T120. (FIG. 1A) Chromatin was prepared from human prostate cancer (DU145) and normal (MLC) cell lines and subjected to western blotting with the indicated antibodies. Ponceau S staining and b-actin served as loading controls in all western blot analyses in this study. Quantifications of the band intensities by densitometry are shown below the western blots, and similar results were obtained from two additional experiments. ac, acetylation; p, phosphorylation; me3, trimethylation. (FIG. 1B) DU145 cells were infected with lentiviruses expressing VprBP shRNA1 (lane 2) or nonspecific control shRNA (lane 1), and chromatin fractions were analyzed by western blotting as in (FIG. 1A). (FIG. 1C) Individual core histones were incubated with recombinant VprBP in the presence of [g-32P] ATP. The reactions were resolved by 15% SDS-PAGE and analyzed by autoradiography (upper panel) and Coomassie blue staining (lower panel). (FIG. 1D) VprBP contains the putative kinase domain in the N-terminal region, the Lis homology motif in the central region, and the WD repeat and D/E-rich motif in the C-terminal region. Numbers denote amino acid positions. Sequence alignment of the putative kinase domain in VprBP (SEQ ID NOS 4-5, 59 and 6-10, respectively, in order of appearance) with the kinase domains of human CK1 (SEQ ID NOS 60-67, respectively, in order of appearance) and Mut9p (SEQ ID NOS 68-69, 62 and 70-74, respectively, in order of appearance) is shown in the lower panel. The boxed regions correspond to the conserved kinase subdomains I-III and V-IX. (FIG. 1E) Nucleosomes were reconstituted on a 207 bp 601 nt positioning sequence using recombinant histones and incubated with wild-type VprBP or the indicated mutants. H2A phosphorylation was detected by autoradiography. (FIG. 1F) Kinase assays were performed as in (FIG. 1E) but using nucleosomes containing wild-type, tailless, or mutant H2A (SEQ ID NOS 75-78, respectively, in order of appearance). The residues that were mutated are indicated at the top. The H2A mutations did not affect histone octamer and nucleosome formation during reconstitution (data not shown). (FIG. 1G) Nucleosomes containing H2A wild-type or T120A mutant were incubated with VprBP and ATP. H2AT120p was analyzed by western blotting with anti-H2AT120p antibody. See also FIG. 5.

FIGS. 2A-2D show that VprBP is overexpressed in tumors and required for cell proliferation. (FIG. 2A) Tissue microarrays containing primary tumor and adjacent normal samples from cancer patients were subjected to immunohistochemistry with VprBP and H2AT120p antibodies. High-power magnifications are shown for six representative samples. Scale bars correspond to 50 mm. See also Table 1. (FIG. 2B) DU145 cells were depleted of VprBP and infected with lentiviruses expressing the VprBP wild-type (WT) or VprBP kinase-dead mutant K194R (KD). The levels of VprBP and H2AT120p were determined by western blotting. (FIG. 2C) VprBP-depleted DU145 cells were complemented with VprBP WT or KD, and cell proliferation was measured by MTT assay. Results represent the means±SD of three experiments performed in triplicate. (FIG. 2D) VprBP-depleted DU145 cells were infected with VprBP WT or KD as in (FIG. 2C), and the colonies grown up in soft agar were stained and counted. The y axis indicates the number of colonies with a diameter of >0.05 mm per view. Three independent experiments in triplicate wells were performed. Data represent the means±SD of three independent experiments. See also FIG. 6.

FIGS. 3A-3E show functional analysis of VprBP-mediated H2AT120p. (FIG. 3A) Chromatin templates containing wild-type or T120-mutated H2A were transcribed in the presence of Gal4-VP16, p300+AcCoA, and/or VprBP as indicated above the panel. VprBP was added to the reaction before p300. The results shown are representative of three independent experiments. (FIG. 3B) Shown are scatterplots of the global gene expression patterns comparing VprBP-depleted DU145 cells with mock-depleted cells. Dots represent expression values for the genes with a change >1.7-fold in either of two independent experiments. (FIG. 3C) Clustering and heatmap representation of the genes upregulated upon VprBP depletion and related to cell death and proliferation. Yellow and blue indicate high and low expression, respectively. See also Tables 2 and 3. (FIG. 3D) RNA was isolated from VprBP-depleted DU145 cells as in (FIG. 3B) and subjected to real-time qRT-PCR using primers specific for the indicated genes and listed in Experimatal Procedures. Expression levels were normalized to b-actin level and shown relative to those of mock-depleted cells, and were arbitrarily assigned a value of 1. Data represent the means=SD of three independent experiments. (FIG. 3E) The levels of H2AT120p, H2A, VprBP, and H3 at the OPN3 gene were assessed in mock- and VprBP-depleted DU145 cells by ChIP analysis. Precipitation efficiencies were determined for promoter (P), transcription start site (TSS), and coding region (CR) by quantitative PCR (qPCR) with primers listed in Experimental Procedures. Quantitative results were averaged from three separate determinations. Results represent the means±SD of three independent experiments. See also FIG. 7.

FIGS. 4A-4J show discovery and characterization of a small-molecule VprBP inhibitor. (FIG. 4A) In vitro kinase assays were performed with recombinant H2A and VprBP in the presence of the indicated compounds (5 mM). The effects of the compounds were evaluated by western blotting with H2AT120p antibody. (FIG. 4B) DU145 cells were grown in the presence of the indicated concentrations of either B32B3 or B20H6 for 24 hr and immunoblotted with H2A and H2AT120p antibodies. (FIG. 4C) Molecular structure of B32B3. (FIG. 4D) DU145 cells were treated with DMSO or 0.5 mM B32B3 for 24 hr. The cellular levels of H2AT120p were assessed by immunostaining. (FIG. 4E) DU145 cells were treated with increasing concentrations of B32B3 for 24 hr, and the colonies were counted 3 weeks after seeding the cells on soft agar. The data are the means of three independent experiments ±SD. (FIG. 4F) Nude mice were implanted with 1 3 107 DU145 cells on the left flank. Five days after implantation, mice bearing established tumors were randomized into groups and treated with twice-weekly i.p. injections of either DMSO or B32B3 at a dose of 5 mg/kg (n=8 per group). Tumor volumes (mm3) were measured at the indicated time points and shown as mean tumor volumes ±SEM. (FIG. 4G) Mice were killed at day 25 of the tumor growth, and the tumors were dissected and weighed. Mean tumor weights ±SEM are shown, and the p value was calculated by unpaired Student's t test. (FIG. 411) DU145 xenografts were excised from DMSO-treated and B32B3-treated mice, and were analyzed by immunohistochemistry. Representative view was photographed. (FIG. 4I) Relative mRNA levels of the VprBP target genes in DMSO-treated (black bars) and B32B3-treated (1 mM, gray bars) DU145 cells were determined by qRT-PCR. Data represent the means±SD of three independent experiments. (FIG. 4J) DU145 cells exposed to DMSO or 1 mM B32B3 were subject to ChIP analysis using the indicated antibodies. The data are the means of three independent experiments ±SD. See also FIG. 8.

FIGS. 5A-5M show phosphorylation of H2A T120 bp VprBP, related to FIG. 1. (FIG. 5A) Chromatin was isolated from human bladder (LD611) and breast (MDA-MB231) cancer cell lines and their normal counterparts (Urotsa and MCF-10-2A). The levels of the indicated histone modifications were assessed by Western blotting as in FIG. 1A. (FIG. 5B) LD611 bladder and MDA-MB231 breast cancer cell lines were infected with a VprBP shRNA and examined for the indicated histone modifications by Western blotting. (FIG. 5C) Recombinant VprBP proteins were expressed in Sf9 cells and purified as described under Experimental Procedures. The purity of the proteins used in this study was confirmed by SDS-PAGE and subsequent silver staining. (FIG. 5D) The purity of the recombinant VprBP wild type purified in (FIG. 5C) was determined by mass spectrometry. (FIG. 5E) Individual core histones were incubated with VprBP in the presence of [3H]-AcCoA or [3H]-SAM, and their modifications were determined by autoradiography. As positive controls, p300 (acetylating all four core histones) and Set7 (methylating H3K4) were included in the assays. (FIG. 5F) In vitro kinase assays were performed as in FIG. 1C, but using reconstituted nucleosomes containing untagged H2A (lanes 1 and 2) or Flag-tagged H2A (lanes 3 and 4). (FIG. 5G) Mononucleosomes were immobilized on streptavidin-agarose beads and incubated with VprBP in the presence of 10 mM ATP. After extensive washing, intranucleosomal H2AT120p was accessed by immunoblotting with H2A and H2AT120p antibodies. (FIG. 5H) In vitro kinase assays were performed with recombinant H2A and endogenous VprBP immunoprecipitated from DU145 cells. (FIG. 5I) The recombinant VprBP (5 μg) was separated on an 8% SDS-PAGE gel, denatured with 6M guanidine HCl for 1 h and renatured for 16 h. To detect autophosphorylation of VprBP, the gel was soaked in kinase buffer in the presence of [γ-32P]ATP (20 Ci/ml) for 1 h, washed stringently for 2 h, dried, and visualized by autoradiography. (FIG. 5J) Wild type and mutant VprBP proteins were run on a denaturing gel, refolded, and subjected to in situ kinase assay as in FIG. 5I. (FIG. 5K) CD values were determined using 1 μM VprBP proteins in the range of 200-260 nm. CD spectra are the average of 20 measurements. (FIG. 5L) DU145 cells were infected with Bub1 shRNA, and the levels of H2AT120p were determined by Western blot analysis of cell extracts. (FIG. 5M) Whole cell extract were prepared in MLC and DU145 cells, and total Bub1 expression levels were analyzed by Western blotting.

FIGS. 6A-6F show effects of knockdown and overexpression VprBP on cell proliferation, related to FIG. 2. (FIG. 6A) DU145 cancer cells were depleted of VprBP using another shRNA, as confirmed by Western blotting. (FIG. 6B) DU145 cells depleted of VprBP in (FIG. 6A) were subjected to MTT assays over a period of 5 days. Results are the means±S.D. of three experiments performed in triplicate. (FIG. 6C) DU145 cells depleted of VprBP in (FIG. 6A) were subjected to colony formation assays as described in FIG. 2D. Data represent the means±S.D. of three independent experiments. (FIG. 6D) MLC cells were infected with lentiviruses expressing VprBP, and the levels of VprBP and H2AT120p were assessed by Western blotting. (FIG. 6E) VprBP was overexpressed in MLC cells as in (FIG. 6D), and its effects on cell proliferation were determined by MTT assay over a period of 5 days. Average and standard deviation are shown for three independent experiments. (FIG. 6F) Colony formation assays were carried out as in (FIG. 6C), but using MLC cells overexpressing VprBP. Average and standard deviation of three independent experiments are shown.

FIGS. 7A-7C show that H2AT120p is required for the transrepression activity of VprBP, related to FIG. 3. (FIG. 7A) In vitro transcription assays were performed using chromatin templates containing wild type or T120-mutated H2A as in FIG. 3A, but in the absence of ATP. (FIG. 7B) The 292 genes identified as being upregulated upon VprBP knockdown from the microarray analysis were subjected to functional enrichment analysis using DAVID. The blue and red bars represent the number of enriched genes and p-values for the enrichment, respectively. (FIG. 7C) ChIP assays of four VprBP target genes (NOV, SOCS2, SOCS3 and TNFSF10) and one control gene (RARRES1) were performed as in FIG. 3E using the indicated antibodies. The precipitated DNA was quantified by qPCR with the primers listed in Experimental Procedures. Results represent the means±S.D. of three independent experiments.

FIGS. 8A-8I show characterization of B32B3 as a small-molecule VprBP kinase inhibitor, related to FIG. 4. (FIG. 8A) DU145 cells were infected with mock lentiviruse, VprBP-expressing shRNA lentivirus or Flag-VprBP-expressing lentivirus, and treated with the indicated concentrations of B32B3 for 24 h. Changes in H2AT120p as the results of B32B3 treatment were determined by the quantitative estimates of Western band intensity. Results represent the means±S.D. of three independent experiments. (FIG. 8B) DU145 cells were treated with the indicated concentrations of B32B3 and B20H6 for 72 h. Cell viability was measured by the MTT assay and was normalized to cells not exposed to the compounds. Data represent the means±S.D. of three independent experiments. (FIG. 8C) MLC cells were grown in the presence of the indicated concentrations of B32B2 for 24 h, and subjected to immunoblotting with H2AT120p and H2A antibodies. (FIG. 8D) MLC cells were treated with B32B3 at the indicated doses for 24 h, and cell viability was assessed by MTT assay. Average and standard deviation of three independent experiments are shown. (FIG. 8E) VprBP-mediated H2AT120p was analyzed in the presence of increasing concentrations of ATP and B32B3. (FIG. 8F) Body weights of vehicle or B32B3-treated mice were monitored during the treatment period. Mean body weights ±S.E.M. are shown. (FIG. 8G) B32B3 was spiked into the indicated blank plasma to a concentration of 10 μM. The stability of B32B3 in plasma was determined by LC-MS/MS at the indicated time points. Results are shown as the mean of three independent experiments ±S.D. (FIG. 8H) B32B3 was administered to mice (n=5) at a dose of 5 mg/kg. Blood samples were collected at the indicated time points, and the concentration of B32B3 in plasma was analyzed by HPLCcoupled mass spectrophotometry. The data are shown as the mean±S.D. (FIG. 8I) B32B3-treated DU145cells were subjected to ChIP analysis as in FIG. 4I using indicated antibodies. Average and standard deviation are shown for three independent experiments.

FIG. 9 shows domain architecture and known mutation sites of VprBP. VprBP contains the putative kinase domain in the N-terminus and the Lis homology motif, WD repeats and D/E rich domains in the C-terminus. Numbers denote amino acid positions. The positions of known mutation in the kinase domain are indicated by letters along with their positions. FIG. 9 discloses VprBP as SEQ ID NOS 4-5, 59, 6-9 and 79, respectively, in order of appearance, CK1 as SEQ ID NOS 60-66 and 80, respectively, in order of appearance and Mut9p as SEQ ID NOS 68-69, 62, 70-73 and 81, respectively, in order of appearance.

FIG. 10 shows VprBP functions in chromatin silencing. VprBP is localized onto specific chromatin regions via its interaction with the H3 N-terminal tail (NT) and phosphorylates H2A C-terminal tail (CT) at T120 to establish a repressive chromatin state. Thus free H3 tail peptides can prevent VprBP from binding to the nucleosome and thereby inhibit H2AT120 phosphorylation reactions.

DETAILED DESCRIPTION

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices and materials are now described. All technical and patent publications cited herein are incorporated herein by reference in their entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of tissue culture, immunology, molecular biology, microbiology, cell biology and recombinant DNA, which are within the skill of the art. See, e.g., Sambrook and Russell eds. (2001) Molecular Cloning: A Laboratory Manual, 3^(rd) edition; the series Ausubel et al. eds. (2007) Current Protocols in Molecular Biology; the series Methods in Enzymology (Academic Press, Inc., N.Y.); MacPherson et al. (1991) PCR 1: A Practical Approach (IRL Press at Oxford University Press); MacPherson et al. (1995) PCR 2: A Practical Approach; Harlow and Lane eds. (1999) Antibodies, A Laboratory Manual; Freshney (2005) Culture of Animal Cells: A Manual of Basic Technique, 5^(th) edition; Gait ed. (1984) Oligonucleotide Synthesis; U.S. Pat. No. 4,683,195; Hames and Higgins eds. (1984) Nucleic Acid Hybridization; Anderson (1999) Nucleic Acid Hybridization; Hames and Higgins eds. (1984) Transcription and Translation; Immobilized Cells and Enzymes (IRL Press (1986)); Perbal (1984) A Practical Guide to Molecular Cloning; Miller and Calos eds. (1987) Gene Transfer Vectors for Mammalian Cells (Cold Spring Harbor Laboratory); Makrides ed. (2003) Gene Transfer and Expression in Mammalian Cells; Mayer and Walker eds. (1987) Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); and Herzenberg et al. eds (1996) Weir's Handbook of Experimental Immunology.

The term “about” when used with numerical designations, e.g., pH, temperature, time, amount, concentration and molecular weight, including ranges, refers to approximations which are varied (+) or (−) by increments of 1.0 or 0.1, as appropriate, or alternatively by a variation of +/−15%, or alternatively 10%, or alternatively 5% or alternatively 2%.

As used in the specification and claims, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a polypeptide” includes a plurality of polypeptides, including mixtures thereof.

As used herein, the term “comprising” is intended to mean that the compositions and methods include the recited elements, but do not exclude others. “Consisting essentially of” when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination for the intended use. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives and the like. “Consisting of” shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Embodiments defined by each of these transition terms are within the scope of this invention.

The term “VprBP” refers to a nuclear protein that can interact with HIV viral protein R and Cullin 4-DDB 1 ubiquitin ligase complex which is reported in Li, W. et al. ((2010) Cell 140:477-490), including the wild type VprBP and mutated VprBP, such as those described in the Experimental section.

The term “VprBP kinase activity” refers to VprBP's activity of phosphorylating another protein. In some embodiments, the protein that is phosphorylated by VprBP is a histone, a protein found in eukaryotic cell nuclei that packages and orders the DNA into structural units called nucleosomes, described in, for example, Suganuma, T. et al. ((2011) Annu. Rev. Biochem. 80:473-499) and Banerjee, T. et al. ((2011) Mol. Cell. Biol. 31:4858-4873). In some embodiments, the protein that is phosphorylated by VprBP is histone H2A at, for example, threonine 120.

The term “VprBR-related cancer” intends a cancer or tumor that is caused by in whole or in part by the misregulation of VprBP phosphorylation of a histone.

The term “H2AT120p” refers to histone H2A phosphorylated at threonine 120.

The term “isolated” as used herein with respect to nucleic acids, such as DNA or RNA, refers to molecules separated from other DNAs or RNAs, respectively that are present in the natural source of the macromolecule. The term “isolated peptide fragment” is meant to include peptide fragments which are not naturally occurring as fragments and would not be found in the natural state. The term “isolated” is also used herein to refer to polypeptides and proteins that are isolated from other cellular proteins and is meant to encompass both purified and recombinant polypeptides. In other embodiments, the term “isolated” means separated from constituents, cellular and otherwise, in which the cell, tissue, polynucleotide, peptide, polypeptide, protein, antibody or fragment(s) thereof, which are normally associated in nature. For example, an isolated cell is a cell that is separated form tissue or cells of dissimilar phenotype or genotype. As is apparent to those of skill in the art, a non-naturally occurring polynucleotide, peptide, polypeptide, protein, antibody or fragment(s) thereof, does not require “isolation” to distinguish it from its naturally occurring counterpart.

The term “purified” refers to a composition being substantially free from contaminants. With respect to polynucleotides and polypeptides, purified intends the composition being substantially free from contamination from polynucleotides or polypeptides with different sequences. In certain embodiments, it also refers to polynucleotides and polypeptides substantially free from cell debris or cell culture media.

The term “recombinant” refers to, in one aspect, a form of artificial DNA that is created by combining two or more sequences that would not normally occur in their natural environment. In another aspect, “recombinant” intends isolated DNA that is replicated in an artificial system. A recombinant protein is a protein that is derived from recombinant DNA.

The term “protein”, “peptide” and “polypeptide” are used interchangeably and in their broadest sense refer to a compound of two or more subunit amino acids, amino acid analogs or peptidomimetics. The subunits may be linked by peptide bonds. In another embodiment, the subunit may be linked by other bonds, e.g., ester, ether, etc. A protein or peptide must contain at least two amino acids and no limitation is placed on the maximum number of amino acids which may comprise a protein's or peptide's sequence. As used herein the term “amino acid” refers to either natural and/or unnatural or synthetic amino acids, including glycine and both the D and L optical isomers, amino acid analogs and peptidomimetics.

“Homology” or “identity” or “similarity” refers to two nucleic acid molecules that hybridize under stringent conditions to the reference polynucleotide or its complement.

“Hybridization” refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues. The hydrogen bonding may occur by Watson-Crick base pairing, Hoogstein binding, or in any other sequence-specific manner. The complex may comprise two strands forming a duplex structure, three or more strands forming a multi-stranded complex, a single self-hybridizing strand, or any combination of these. A hybridization reaction may constitute a step in a more extensive process, such as the initiation of a PCR reaction, or the enzymatic cleavage of a polynucleotide by a ribozyme.

Examples of stringent hybridization conditions include: incubation temperatures of about 25° C. to about 37° C.; hybridization buffer concentrations of about 6×SSC to about 10×SSC; formamide concentrations of about 0% to about 25%; and wash solutions from about 4×SSC to about 8×SSC. Examples of moderate hybridization conditions include: incubation temperatures of about 40° C. to about 50° C.; buffer concentrations of about 9×SSC to about 2×SSC; formamide concentrations of about 30% to about 50%; and wash solutions of about 5×SSC to about 2×SSC. Examples of high stringency conditions include: incubation temperatures of about 55° C. to about 68° C.; buffer concentrations of about 1×SSC to about 0.1×SSC; formamide concentrations of about 55% to about 75%; and wash solutions of about 1×SSC, 0.1×SSC, or deionized water. In general, hybridization incubation times are from 5 minutes to 24 hours, with 1, 2, or more washing steps, and wash incubation times are about 1, 2, or 15 minutes. SSC is 0.15 M NaCl and 15 mM citrate buffer. It is understood that equivalents of SSC using other buffer systems can be employed.

As used herein, the terms “treat”, “treating,” or “treatment” and the like are used herein to mean obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disorder or sign or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disorder and/or adverse effect attributable to the disorder.

To “prevent” intends to prevent a disorder or effect in vitro or in vivo in a system or subject that is predisposed to the disorder.

The term “tumor suppression” refers to slowing down the growth of a tumor, stopping the growth of a tumor or reducing the size of existing tumor.

The term “inhibiting H2AT120p” refers to inhibiting the phosphorylation of histone H2A on threonine 120 and/or inhibiting the activity of histone H2A phosphorylated on threonine 120.

The term “VprBP inhibitor” refers to a compound or other agent such as RNAi that reduces the activity of VprBP. In some embodiments, the compound inhibits VprBP with a half maximal inhibitory concentration (IC₅₀) value of no more than about 10 μM, or no more than about 5 μM, or no more than about 1 μM.

The term “small molecule VprBP inhibitor” refers to a VprBP inhibitor with a molecular weight of no more than about 1,500 Daltons, or no more than about 1,000 Daltons, or no more than about 900 Daltons.

In some embodiments, the small molecule inhibitor of VprBP is B32B3, a compound of the formula:

or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof.

In some embodiments, the small molecule inhibitor of VprBP can be prepared according methods and using intermediates known in the art such as those described in U.S. Pat. No. 3,878,201 or PCT International Application Publication No. WO 2013/072921 and T. Baburaj a, S. Thambidurai, Synlett, 2011, 1993-1996.

In some embodiments, the small molecule inhibitor of VprBP can be prepared according to Scheme 1:

As shown in Scheme 1, Compound 1 (ChemExper, Belgium) can react with Compound 2 to give Compound 3 in a hydrophilic solvent such as ethanol, propanol, butanol, dioxane, etc., at an elevated temperature such as about 75° to 150° C., optionally in the presence of a catalytic amount of an acid, such hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, hydrogen iodide, maleic acid, fumaric acid, etc. R in Compound 2 is H or an amino protecting group, such as tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), or [(9-fluorenylmethyl)oxy]carbonyl (Fmoc). When R is H, Compound 2 is 1H-indole-3-carbaldehyde (ChemExper, Belgium) and the reaction in Scheme 1 produces B32B3 directly. When R is an amino protecting group, Compound 2 can be prepared from 1H-indole-3-carbaldehyde with methods known in the art. After reaction of Compound 1 and Compound 2, the protecting group can be removed under conditions known in the art, such as acidic condition when R is Boc, hydrogenation condition when R is Cbz, and basic condition when R is Fmoc. Additional amino protecting groups, the conditions to add a protect group to 1H-indole-3-carbaldehyde, and conditions to remove the protect group are known in the art, for example, described in T. W. Greene and P. G. M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York, 1999, and references cited therein.

“Pharmaceutically acceptable salt” refers to salts of a compound, which salts are suitable for pharmaceutical use and are derived from a variety of organic and inorganic counter ions well known in the art and include, when the compound contains an acidic functionality, by way of example only, sodium, potassium, calcium, magnesium, ammonium, and tetraalkylammonium; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, and oxalate (see Stahl and Wermuth, eds., “HANDBOOK OF PHARMACEUTICALLY ACCEPTABLE SALTS,” (2002), Verlag Helvetica Chimica Acta, Zurich, Switzerland), for a discussion of pharmaceutical salts, their selection, preparation, and use.

Generally, pharmaceutically acceptable salts are those salts that retain substantially one or more of the desired pharmacological activities of the parent compound and which are suitable for in vivo administration. Pharmaceutically acceptable salts include acid addition salts formed with inorganic acids or organic acids. Inorganic acids suitable for forming pharmaceutically acceptable acid addition salts include, by way of example and not limitation, hydrohalide acids (e.g., hydrochloric acid, hydrobromic acid, hydroiodic acid, etc.), sulfuric acid, nitric acid, phosphoric acid, and the like.

Organic acids suitable for forming pharmaceutically acceptable acid addition salts include, by way of example and not limitation, acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, oxalic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, palmitic acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, alkylsulfonic acids (e.g., methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, etc.), arylsulfonic acids (e.g., benzenesulfonic acid, 4 chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, etc.), glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like.

Pharmaceutically acceptable salts also include salts formed when an acidic proton present in the parent compound is either replaced by a metal ion (e.g., an alkali metal ion, an alkaline earth metal ion, or an aluminum ion) or by an ammonium ion (e.g., an ammonium ion derived from an organic base, such as, ethanolamine, diethanolamine, triethanolamine, morpholine, piperidine, dimethylamine, diethylamine, triethylamine, and ammonia).

A solvate of a compound is a solid-form of the compound that crystallizes with less than one, one or more than one molecules of solvent inside in the crystal lattice. A few examples of solvents that can be used to create solvates, such as pharmaceutically acceptable solvates, include, but are not limited to, water, C₁-C₆ alcohols (such as methanol, ethanol, isopropanol, butanol, and can be optionally substituted) in general, tetrahydrofuran, acetone, ethylene glycol, propylene glycol, acetic acid, formic acid, and solvent mixtures thereof. Other such biocompatible solvents which may aid in making a pharmaceutically acceptable solvate are well known in the art. Additionally, various organic and inorganic acids and bases can be added to create a desired solvate. Such acids and bases are known in the art. When the solvent is water, the solvate can be referred to as a hydrate. In some embodiments, one molecule of a compound can form a solvate with from 0.1 to 5 molecules of a solvent, such as 0.5 molecules of a solvent (hemisolvate, such as hemihydrate), one molecule of a solvent (monosolvate, such as monohydrate) and 2 molecules of a solvent (disolvate, such as dihydrate).

“RNA interference” (RNAi) refers to sequence-specific or gene specific suppression of gene expression (protein synthesis) that is mediated by short interfering RNA (siRNA).

“Short interfering RNA” (siRNA) refers to double-stranded RNA molecules (dsRNA), generally, from about 10 to about 30 nucleotides in length that are capable of mediating RNA interference (RNAi), or 11 nucleotides in length, 12 nucleotides in length, 13 nucleotides in length, 14 nucleotides in length, 15 nucleotides in length, 16 nucleotides in length, 17 nucleotides in length, 18 nucleotides in length, 19 nucleotides in length, 20 nucleotides in length, 21 nucleotides in length, 22 nucleotides in length, 23 nucleotides in length, 24 nucleotides in length, 25 nucleotides in length, 26 nucleotides in length, 27 nucleotides in length, 28 nucleotides in length, or 29 nucleotides in length. As used herein, the term siRNA includes short hairpin RNAs (shRNAs). A siRNA directed to a gene or the mRNA of a gene may be a siRNA that recognizes the mRNA of the gene and directs a RNA-induced silencing complex (RISC) to the mRNA, leading to degradation of the mRNA. A siRNA directed to a gene or the mRNA of a gene may also be a siRNA that recognizes the mRNA and inhibits translation of the mRNA. The siRNA can be administered as naked DNA or within an expression or delivery vehicle.

“Double stranded RNA” (dsRNA) refer to double stranded RNA molecules that may be of any length and may be cleaved intracellularly into smaller RNA molecules, such as siRNA. In cells that have a competent interferon response, longer dsRNA, such as those longer than about 30 base pair in length, may trigger the interferon response. In other cells that do not have a competent interferon response, dsRNA may be used to trigger specific RNAi.

microRNA or miRNA are single-stranded RNA molecules of 21-23 nucleotides in length, which regulate gene expression. miRNAs are encoded by genes from whose DNA they are transcribed but miRNAs are not translated into protein (non-coding RNA); instead each primary transcript (a pri-miRNA) is processed into a short stem-loop structure called a pre-miRNA and finally into a functional miRNA. Mature miRNA molecules are partially complementary to one or more messenger RNA (mRNA) molecules, and their main function is to down-regulate gene expression.

A siRNA vector, dsRNA vector or miRNA vector as used herein, refers to a plasmid or viral vector comprising a promoter regulating expression of the RNA. “siRNA promoters” or promoters that regulate expression of siRNA, dsRNA, or miRNA are known in the art, e.g., a U6 promoter as described in Miyagishi and Taira (2002) Nature Biotech. 20:497-500, and a H1 promoter as described in Brummelkamp et al. (2002) Science 296:550-3.

As used herein, “expression” refers to the process by which polynucleotides are transcribed into mRNA and/or the process by which the transcribed mRNA is subsequently being translated into peptides, polypeptides, or proteins. If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in an eukaryotic cell.

Various proteins are also disclosed herein with their GenBank Accession Numbers for their human proteins and coding sequences. However, the proteins are not limited to human-derived proteins having the amino acid sequences represented by the disclosed GenBank Accession numbers, but may have an amino acid sequence derived from other animals, particularly, a warm-blooded animal (e.g., rat, guinea pig, mouse, chicken, rabbit, pig, sheep, cow, monkey, etc.).

A “gene delivery vehicle” is defined as any molecule that can carry inserted polynucleotides into a host cell. Examples of gene delivery vehicles are liposomes, micelles, biocompatible polymers, including natural polymers and synthetic polymers; lipoproteins; polypeptides; polysaccharides; lipopolysaccharides; artificial viral envelopes; metal particles; and bacteria, or viruses, such as baculovirus, adenovirus and retrovirus, bacteriophage, cosmid, plasmid, fungal vectors and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression.

A polynucleotide of this invention can be delivered to a cell or tissue using a gene delivery vehicle. “Gene delivery,” “gene transfer,” “transducing,” and the like as used herein, are terms referring to the introduction of an exogenous polynucleotide (sometimes referred to as a “transgene”) into a host cell, irrespective of the method used for the introduction. Such methods include a variety of well-known techniques such as vector-mediated gene transfer (by, e.g., viral infection/transfection, or various other protein-based or lipid-based gene delivery complexes) as well as techniques facilitating the delivery of “naked” polynucleotides (such as electroporation, “gene gun” delivery and various other techniques used for the introduction of polynucleotides). The introduced polynucleotide may be stably or transiently maintained in the host cell. Stable maintenance typically requires that the introduced polynucleotide either contains an origin of replication compatible with the host cell or integrates into a replicon of the host cell such as an extrachromosomal replicon (e.g., a plasmid) or a nuclear or mitochondrial chromosome. A number of vectors are known to be capable of mediating transfer of genes to mammalian cells, as is known in the art and described herein.

Gene delivery vehicles also include DNA/liposome complexes, micelles and targeted viral protein-DNA complexes. Liposomes that also comprise a targeting antibody or fragment thereof can be used in the methods of this invention. To enhance delivery to a cell, the nucleic acid or proteins of this invention can be conjugated to antibodies or binding fragments thereof which bind cell surface antigens. In addition to the delivery of polynucleotides to a cell or cell population, direct introduction of the proteins described herein to the cell or cell population can be done by the non-limiting technique of protein transfection, alternatively culturing conditions that can enhance the expression and/or promote the activity of the proteins of this invention are other non-limiting techniques.

“Administration” can be effected in one dose, continuously or intermittently throughout the course of treatment. Methods of determining appropriate means and dosage of administration are known to those of skill in the art and will vary with the composition used for therapy, the purpose of the therapy, the target cell being treated and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician. Suitable dosage formulations and methods of administering the agents are known in the art. Route of administration can also be determined and method of determining appropriate route of administration are known to those of skill in the art and will vary with the composition used for treatment, the purpose of the treatment, the health condition or disease stage of the subject being treated and target cell or tissue. Non-limiting examples of route of administration include oral administration, nasal administration, injection and topical application.

The term “effective amount” refers to a quantity sufficient to achieve a beneficial or desired result or effect. In the context of therapeutic or prophylactic applications, the effective amount will depend on the type and severity of the condition at issue and the characteristics of the individual subject, such as general health, age, sex, body weight, and tolerance to pharmaceutical compositions. The skilled artisan will be able to determine appropriate amounts depending on these and other factors.

In the case of an in vitro application, in some embodiments the effective amount will depend on the size and nature of the application in question. It will also depend on the nature and sensitivity of the in vitro target and the methods in use. The skilled artisan will be able to determine the effective amount based on these and other considerations. The effective amount may comprise one or more administrations of a composition depending on the embodiment.

A “subject,” “individual” or “patient” is used interchangeably herein, and refers to a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, murines, rats, rabbits, simians, bovines, ovines, porcines, canines, felines, farm animals, sport animals, pets, equines, and primates, particularly humans.

The agents and compositions can be used in the manufacture of medicaments and for the treatment of humans and other animals by administration in accordance with conventional procedures, such as an active ingredient in pharmaceutical compositions.

An agent of the present invention can be administered for therapy by any suitable route of administration. It will also be appreciated that the preferred route will vary with the condition and age of the recipient and the disease being treated.

A “composition” typically intends a combination of the active agent, e.g., compound or composition, and a carrier, inert (for example, a detectable agent or label) or active, such as an adjuvant, diluent, binder, stabilizer, buffers, salts, lipophilic solvents, preservative, adjuvant or the like and include pharmaceutically acceptable carriers. Carriers also include pharmaceutical excipients and additives proteins, peptides, amino acids, lipids, and carbohydrates (e.g., sugars, including monosaccharides, di-, tri-, tetra-oligosaccharides, and oligosaccharides; derivatized sugars such as alditols, aldonic acids, esterified sugars and the like; and polysaccharides or sugar polymers), which can be present singly or in combination, comprising alone or in combination 1-99.99% by weight or volume. Exemplary protein excipients include serum albumin such as human serum albumin (HSA), recombinant human albumin (rHA), gelatin, casein, and the like. Representative amino acid/antibody components, which can also function in a buffering capacity, include alanine, glycine, arginine, betaine, histidine, glutamic acid, aspartic acid, cysteine, lysine, leucine, isoleucine, valine, methionine, phenylalanine, aspartame, and the like. Carbohydrate excipients are also intended within the scope of this invention, examples of which include but are not limited to monosaccharides such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and the like; polysaccharides, such as raffinose, melezitose, maltodextrins, dextrans, starches, and the like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol sorbitol (glucitol) and myoinositol.

The term carrier further includes a buffer or a pH adjusting agent; typically, the buffer is a salt prepared from an organic acid or base. Representative buffers include organic acid salts such as salts of citric acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid; Tris, tromethamine hydrochloride, or phosphate buffers. Additional carriers include polymeric excipients/additives such as polyvinylpyrrolidones, ficolls (a polymeric sugar), dextrates (e.g., cyclodextrins, such as 2-hydroxypropyl-.quadrature.-cyclodextrin), polyethylene glycols, flavoring agents, antimicrobial agents, sweeteners, antioxidants, antistatic agents, surfactants (e.g., polysorbates such as “TWEEN 20” and “TWEEN 80”), lipids (e.g., phospholipids, fatty acids), steroids (e.g., cholesterol), and chelating agents (e.g., EDTA).

As used herein, the term “pharmaceutically acceptable carrier” encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents. The compositions also can include stabilizers and preservatives and any of the above noted carriers with the additional proviso that they be acceptable for use in vivo. Examples of pharmaceutically acceptable carriers include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances, such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. For examples of carriers, stabilizers and adjuvants, see Martin REMINGTON'S PHARM. SCI., 15th Ed. (Mack Publ. Co., Easton (1975) and Williams & Williams, (1995), and in the “PHYSICIAN'S DESK REFERENCE”, 52^(nd) ed., Medical Economics, Montvale, N.J. (1998).

The invention provides an article of manufacture, comprising packaging material and at least one vial comprising a solution of a VprBP inhibitor as described herein or its biological equivalent with the prescribed buffers and/or preservatives, optionally in an aqueous diluent, wherein said packaging material comprises a label that indicates that such solution can be held over a period of 1, 2, 3, 4, 5, 6, 9, 12, 18, 20, 24, 30, 36, 40, 48, 54, 60, 66, 72 hours or greater. The invention further comprises an article of manufacture, comprising packaging material, a first vial comprising a VprBP inhibitor or its biological equivalent and a second vial comprising an aqueous diluent of prescribed buffer or preservative, wherein said packaging material comprises a label that instructs a patient to reconstitute the therapeutic in the aqueous diluent to form a solution that can be held over a period of twenty-four hours or greater.

The VprBP inhibitor described herein as effective for their intended purpose can be administered to subjects or individuals identified by the methods herein as suitable for the therapy. Therapeutic amounts can be empirically determined and will vary with the pathology being treated, the subject being treated and the efficacy and toxicity of the agent.

In various embodiments of the methods of the invention, the VprBP inhibitor will be administered locally or systemically on a continuous, daily basis, at least once per day (QD) and in various embodiments two (BID), three (TID) or even four times a day. Typically, the therapeutically effective daily dose will be at least about 1 mg, or at least about 10 mg, or at least about 100 mg or about 200-about 500 mg and sometimes, depending on the compound, up to as much as about 1 g to about 2.5 g.

Dosage, toxicity and therapeutic efficacy of compositions described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, to determine the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compositions which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

In one aspect, the VprBP inhibitor is formulated in biodegradable biospheres (e.g., micelles or liposomes) or are coated on solid phase carriers such as or other devices.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such VprBP inhibitor lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

In some embodiments, an effective amount of a composition sufficient for achieving a therapeutic or prophylactic effect, ranges from about 0.000001 mg per kilogram body weight per administration to about 10,000 mg per kilogram body weight per administration. Suitably, the dosage ranges are from about 0.0001 mg per kilogram body weight per administration to about 100 mg per kilogram body weight per administration. Administration can be provided as an initial dose, followed by one or more “booster” doses. Booster doses can be provided a day, two days, three days, a week, two weeks, three weeks, one, two, three, six or twelve months after an initial dose. In some embodiments, a booster dose is administered after an evaluation of the subject's response to prior administrations.

The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to, the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of the therapeutic compositions described herein can include a single treatment or a series of treatments.

As used herein, the term “detectable label” intends a directly or indirectly detectable compound or composition that is conjugated directly or indirectly to the composition to be detected, e.g., N-terminal histadine tags (N-His), magnetically active isotopes, e.g., ¹¹⁵Sn, ¹¹⁷sn and ¹¹⁹Sn, a non-radioactive isotopes such as ¹³C and ¹⁵N, polynucleotide or protein such as an antibody so as to generate a “labeled” composition. The term also includes sequences conjugated to the polynucleotide that will provide a signal upon expression of the inserted sequences, such as green fluorescent protein (GFP) and the like. The label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable. The labels can be suitable for small scale detection or more suitable for high-throughput screening. As such, suitable labels include, but are not limited to magnetically active isotopes, non-radioactive isotopes, radioisotopes, fluorochromes, luminescent compounds, dyes, and proteins, including enzymes. The label may be simply detected or it may be quantified. A response that is simply detected generally comprises a response whose existence merely is confirmed, whereas a response that is quantified generally comprises a response having a quantifiable (e.g., numerically reportable) value such as an intensity, polarization, and/or other property. In luminescence or fluorescence assays, the detectable response may be generated directly using a luminophore or fluorophore associated with an assay component actually involved in binding, or indirectly using a luminophore or fluorophore associated with another (e.g., reporter or indicator) component.

Examples of luminescent labels that produce signals include, but are not limited to bioluminescence and chemiluminescence. Detectable luminescence response generally comprises a change in, or an occurrence of, a luminescence signal. Suitable methods and luminophores for luminescently labeling assay components are known in the art and described for example in Haugland, Richard P. (1996) Handbook of Fluorescent Probes and Research Chemicals (6^(th) ed.). Examples of luminescent probes include, but are not limited to, aequorin and luciferases.

Examples of suitable fluorescent labels include, but are not limited to, fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosin, coumarin, methyl-coumarins, pyrene, Malacite green, stilbene, Lucifer Yellow, Cascade Blue™, and Texas Red. Other suitable optical dyes are described in the Haugland, Richard P. (1996) Handbook of Fluorescent Probes and Research Chemicals (6^(th) ed.).

In another aspect, the fluorescent label is functionalized to facilitate covalent attachment to a cellular component present in or on the surface of the cell or tissue such as a cell surface marker. Suitable functional groups, including, but not are limited to, isothiocyanate groups, amino groups, haloacetyl groups, maleimides, succinimidyl esters, and sulfonyl halides, all of which may be used to attach the fluorescent label to a second molecule. The choice of the functional group of the fluorescent label will depend on the site of attachment to either a linker, the agent, the marker, or the second labeling agent.

Methods and Compostions

This disclosure provides a method for one or more of:

a. inhibiting the growth of a cancer cell;

b. activating tumor suppressor function in a cell comprising functional tumor suppressor genes; and

c. inhibiting H2AT120P in a cell comprising functional H2AT120P,

comprising, or alternatively of consisting essentially of, or yet further consisting of contacting the cell with an effective amount of an agent that inhibits VprBP kinase activity in the cell. In one aspect, the cell to be contacted is one that expresses VprBP kinase activity and/or one with tumor suppressor activity. In one aspect, the cell is a cancer cell and the cancer is a VprBR-related cancer, e.g., one that is selected from the group of a bladder cancer, a breast cancer or a prostate cancer. In a further aspect, the cancer is VprBR kinase-related in that the cancer is the result of lack of functional VprBR kinase activity in the cell or tissue. The cell can be of any appropriate species, e.g., a mammalian or a human cell. In one aspect, the inhibitor is a synthetic peptide comprising a HIV1 TAT sequence and the H3 N-terminal tail domain which corresponds to amino acids 5-27 (QTARKSTGGKAPRKQLATKAARK (human histone H3 N-terminal tail corresponding to amino acids 5-27)-RKKRRQRRR (HIV1 TAT sequence)) (SEQ ID NO: 11), and sequences having at least 80% amino acid sequence identity and having the same or similar biological activity. Since the regulation of H2AT120 phosphorylation is important in the control of cell growth and the establishment and maintenance of gene silencing, the present invention should make it possible to detect and regulate VprBP dysfunction related to cancer development. In addition, the invention provides a method of reducing H2AT120 phosphorylation by using histone H3 tail peptides which block VprBP kinase activity and therefore reduce VprBP carcinogenic potential in cancer cells.

This disclosure also provides a method for inhibiting the growth of a cancer cell in a patient or treating cancer in a patient, comprising administering to the patient in need thereof an effective amount of VprBR kinase-specific RNAi or a small molecule inhibitor of VprBP. In one aspect, the cell to be contacted is one that expresses VprBP kinase activity and/or one with tumor suppressor activity. In one aspect, the cancer is selected from the group of a bladder cancer, a breast cancer or a prostate cancer. In a further aspect, the cancer is VprBR kinase-related in that the cancer is the result of lack of functional VprBR kinase activity in the cell or tissue. The patient is a mammal or a human patient.

The above methods can be performed in vitro or in vivo, and with an agent comprising, or alternatively consisting essentially of, or yet further consisting of, a VprBR kinase-specific RNAi or a small molecule inhibitor of VprBP. The polynucleotides include for example those which are, or that encode VprBR kinase-specific RNA interference (RNAi) such as siRNA, miRNA dsRNA, mRNA and antisense RNA, as well DNA, such as in gene therapy applications.

In one aspect, the small molecule inhibitor of VprBP is a compound of the formula:

or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof or an equivalent thereof.

In another aspect, VprBR kinase-specific RNAi is selected from the group consisting of a reference polynucleotide of VprBP shRNA1, comprising, or alternatively consisting essentially of, or yet further consisting, or a sequence of one or more of (SEQ ID NO: 1: 5′-CGAGAAACTGAGTCAAATGAA-3′), VprBP shRNA2 (SEQ ID NO: 2: 5′-AATCACAGAGTATCTTAGA-3′) and Bub1 shRNA (SEQ ID NO: 3:5′-CGAGGTTAATCCAGCACGTAT-3′), or an equivalent of each thereof, wherein an equivalent thereof comprises a polynucleotide that has at least 80% sequence identity to the reference polynucleotide and inhibits VprBP kinase activity and/or one that hybridizes under conditions of high stringency to the reference polynucleotide or its complement, wherein conditions of high stringency comprise hybridization reaction at about 60° C. in about 1×SSC, and inhibits VprBP kinase activity.

In one aspect, the methods are practiced by administering an effective amount of, or by contacting the cell with, a synthetic peptide comprising, or alternatively consisting essentially of, or yet further consisting of, a HIV1 TAT sequence and the H3 N-terminal tail domain which corresponds to amino acids 5-27 (QTARKSTGGKAPRKQLATKAARK (human histone H3 N-terminal tail corresponding to amino acids 5-27)-RKKRRQRRR (HIV1 TAT sequence)) (SEQ ID NO: 11), and sequences having at least 80% amino acid sequence identity and having the same or similar biological activity. Since the regulation of H2AT120 phosphorylation is important in the control of cell growth and the establishment and maintenance of gene silencing, the present invention should make it possible to detect and regulate VprBP dysfunction related to cancer development.

This disclosure also provides a method of determining whether a patient is more likely or less likely to be diagnosed with a VprBR-related cancer, comprising or alternatively consisting essentially of, or yet further consisting of screening a sample isolated from the patient for the presence of VprBP in a sample of the patient, wherein the presence of VprBP is an indication that the patient is more likekly to be diagnosed with a VprBR-related cancer in the patient and an absence of VprBR is an indication that the patient is less likely to be diagnosed with a VprBR-related cancer, and optionally administering to the patient identified as more likely to be diagnosed with cancer an effective amount of an agent that inhibits VprBP kinase activity. In one aspect, an overexpression of VprBP is indicative of a cancer in the patient and normal or under expression of VprBP is an indicative that the patient is less likely to be diagnosed with a VprBR-related cancer. In one aspect, the cancer is selected from the group of a bladder cancer, a breast cancer or a prostate cancer. In a further aspect, the patient is a mammal such as a human patient. The sample can be a cell sample such as a bladder cell, breast cell or prostate cell. The cell can be a human cell or a mammalian cell.

Also provided are methods for determining the effectiveness of treating a VprBR-related cancer in a patient by VprBP inhibition, comprising comparing the expression level of one or more gene selected from Tables 2 and 3 in a sample isolated of the patient before treatment by administration of a VprBP inhibiting agent with the expression level of the one or more gene in a sample of the patient after treatment, wherein an increased expression of a gene selected from Table 2 or decreased expression of a gene selected from Table 3 is indicative of positive effectiveness of VprBP inhibition in treating the cancer in the patient. In one aspect, the cancer is selected from the group of a bladder cancer, a breast cancer or a prostate cancer. In a further aspect, the patient is a mammal such as a human patient. The sample can be a cell sample such as a bladder cell, breast cell or prostate cell.

Compositions are further provided herein. In one aspect, the composition comprises, or alternatively consists essentially of, or yet further consists of, a carrier and a compound of the formula:

or a pharmaceutically acceptable salt thereof, a solvate or a salt of the sovate or an equivalent of each thereof.

In one aspect, the compound is present in the composition in an amount from about 0.01 mg to 10 g/day or 1 mg/day to 10 g/day.

Further provided are compositions comprising, or alternatively consisting essentially of, or yet further consisting of a carrier and a VprBR kinase-specific RNAi. In one aspect, the VprBR kinase-specific RNAi is selected from the group of reference polynucleotides that consists essentially of or consist of VprBP shRNA1 (SEQ ID NO: 1: 5′-CGAGAAACTGAGTCAAATGAA-3′), VprBP shRNA2 (SEQ ID NO: 2: 5′-AATCACAGAGTATCTTAGA-3′) and Bub1 shRNA (SEQ ID NO: 3:5′-CGAGGTTAATCCAGCACGTAT-3′), or an equivalent thereof, wherein an equivalent thereof comprises a polynucleotide that has at least 80% sequence identity to the reference polynucleotide and inhibits VprBP kinase activity, and/or one that hybridizes under conditions of high stringency to the reference polynucleotide or its complement, wherein conditions of high stringency comprise hybridization reaction at about 60° C. in about 1×SSC and inhibits VprBP kinase activity.

The polynucleotides of this disclosure can be replicated using conventional recombinant techniques in a mammalian or human host system. Alternatively, the polynucleotides can be replicated using PCR technology. PCR is the subject matter of U.S. Pat. Nos. 4,683,195; 4,800,159; 4,754,065; and 4,683,202 and described in PCR: The Polymerase Chain Reaction (Mullis et al. eds, Birkhauser Press, Boston (1994)) and references cited therein. Yet further, one of skill in the art can use the sequences provided herein and a commercial DNA synthesizer to replicate the DNA. Accordingly, this disclosure also provides a process for obtaining the polynucleotides of this disclosure by providing the linear sequence of the polynucleotide, appropriate primer molecules, chemicals such as enzymes and instructions for their replication and chemically replicating or linking the nucleotides in the proper orientation to obtain the polynucleotides. In a separate embodiment, these polynucleotides are further isolated. Still further, one of skill in the art can operatively link the polynucleotides to regulatory sequences for their expression in a host cell, described below. The polynucleotides and regulatory sequences are inserted into the host cell (prokaryotic or eukaryotic) for replication and amplification. The DNA so amplified can be isolated from the cell by methods well known to those of skill in the art. A process for obtaining polynucleotides by this method is further provided herein as well as the polynucleotides so obtained.

Also provided are host cells comprising one or more of the polypeptides or polynucleotides of this disclosure. In one aspect, the polypeptides are expressed and can be isolated from the host cells. In another aspect, the polypeptides are expressed and secreted. In yet another aspect, the polypeptides are expressed and present on the cell surface (extracellularly). Suitable cells containing the inventive polypeptides include prokaryotic and eukaryotic cells, which include, but are not limited to bacterial cells, algae cells, yeast cells, insect cells, plant cells, animal cells, mammalian cells, murine cells, rat cells, sheep cells, simian cells and human cells. A non-limiting example of algae cells is red alga Griffithsia sp. from which Griffithsin was isolated (Toshiyuki et al. (2005) J. Biol. Chem. 280(10):9345-53). A non-limiting example of plant cells is a Nicotiana benthamiana leaf cell from which Griffithsin can be produced in a large scale (O'Keefe (2009) Proc. Nat. Acad. Sci. USA 106(15):6099-6104). Examples of bacterial cells include Escherichia coli (Giomarelli et al. (2006), supra), Salmonella enteric, Streptococcus gordonii and lactobacillus (Liu et al. (2007) Cellular Microbiology 9:120-130; Rao et al. (2005) PNAS 102:11993-11998; Chang et al. (2003) PNAS 100(20):11672-11677; Liu et al. (2006) Antimicrob. Agents & Chemotherapy 50(10):3250-3259). The cells can be purchased from a commercial vendor such as the American Type Culture Collection (ATCC, Rockville Md., USA) or cultured from an isolate using methods known in the art. Examples of suitable eukaryotic cells include, but are not limited to 293T HEK cells, as well as the hamster cell line CHO, BHK-21; the murine cell lines designated NIH3T3, NS0, C127, the simian cell lines COS, Vero; and the human cell lines HeLa, PER.C6 (commercially available from Crucell) U-937 and Hep G2. A non-limiting example of insect cells include Spodoptera frugiperda. Examples of yeast useful for expression include, but are not limited to Saccharomyces, Schizosaccharomyces, Hansenula, Candida, Torulopsis, Yarrowia, or Pichia. See e.g., U.S. Pat. Nos. 4,812,405; 4,818,700; 4,929,555; 5,736,383; 5,955,349; 5,888,768 and 6,258,559.

For the compositions of this disclosure, the carrier is a pharmaceutically acceptable carrier or an in situ device. In one aspect, the device is a catheter.

Also provided are reference of a sequence selected from the group of:

a. Q-PLRTYSTGLLGGAMENQDI (SEQ ID NO: 4);

b. EVALRQENKRPSPRKLS (SEQ ID NO: 5);

c. DPDRMFVELSNSSWSEMSPWVIGTNYTLYPMTPAIEQRL (SEQ ID NO: 6);

d. YIDLKQTNDVL (SEQ ID NO: 7);

e. FATEFV (SEQ ID NO: 8);

f. KLLEIPRPS (SEQ ID NO: 9);

g. QDAMERVCM (SEQ ID NO: 10);

h. QTARKSTGGKAPRKQLATKAARK (human histone H3 N-terminal tail corresponding to amino acids 5-27)-RKKRRQRRR (HIV1 TAT sequence) (SEQ ID NO: 11); or

i. a polypeptide comprising at least two of a. through h.; or

j. or an equivalent thereof, wherein an equivalent thereof comprises a polypeptide that has at least 80% sequence identity to the reference polypeptide, and/or a polypeptide encoded by a polynucleotide that hybridizes under conditions of high stringency to a polynucleotide or its complement that encodes the reference polypeptide, wherein conditions of high stringency comprise hybridization reaction at about 60° C. in about 1×SSC.

Isolated polynucleotides encoding the polypeptides are further provided. The polypeptides and/or polynucleotides can be combined with a carrier, such as a pharmaceutically acceptable carrier or contained within a host cell, e.g., a mammalian cell.

Polypeptides comprising the amino acid sequences for use in the methods of the disclosure can be prepared by expressing polynucleotides encoding the polypeptide sequences of this disclosure in an appropriate host cell. This can be accomplished by methods of recombinant DNA technology known to those skilled in the art. Accordingly, this disclosure also provides methods for recombinantly producing the polypeptides of this disclosure in a eukaryotic or prokaryotic host cells, as well as the isolated host cells used to produce the proteins. The proteins and polypeptides of this disclosure also can be obtained by chemical synthesis using a commercially available automated peptide synthesizer such as those manufactured by Perkin Elmer/Applied Biosystems, Inc., Model 430A or 431A, Foster City, Calif., USA. The synthesized protein or polypeptide can be precipitated and further purified, for example by high performance liquid chromatography (HPLC). Accordingly, this disclosure also provides a process for chemically synthesizing the proteins of this disclosure by providing the sequence of the protein and reagents, such as amino acids and enzymes and linking together the amino acids in the proper orientation and linear sequence.

It is known to those skilled in the art that modifications can be made to any peptide to provide it with altered properties. Polypeptides of the disclosure can be modified to include unnatural amino acids. Thus, the peptides may comprise D-amino acids, a combination of D- and L-amino acids, and various “designer” amino acids (e.g., β-methyl amino acids, C-α-methyl amino acids, and N-α-methyl amino acids, etc.) to convey special properties to peptides. Additionally, by assigning specific amino acids at specific coupling steps, peptides with α-helices, β turns, β sheets, α-turns, and cyclic peptides can be generated. Generally, it is believed that α-helical secondary structure or random secondary structure is preferred.

In a further embodiment, subunits of polypeptides that confer useful chemical and structural properties will be chosen. For example, peptides comprising D-amino acids may be resistant to L-amino acid-specific proteases in vivo. Modified compounds with D-amino acids may be synthesized with the amino acids aligned in reverse order to produce the peptides of the disclosure as retro-inverso peptides. In addition, the present disclosure envisions preparing peptides that have better defined structural properties, and the use of peptidomimetics, and peptidomimetic bonds, such as ester bonds, to prepare peptides with novel properties. In another embodiment, a peptide may be generated that incorporates a reduced peptide bond, i.e., R₁—CH₂NH—R₂, where R₁, and R₂ are amino acid residues or sequences. A reduced peptide bond may be introduced as a dipeptide subunit. Such a molecule would be resistant to peptide bond hydrolysis, e.g., protease activity. Such molecules would provide ligands with unique function and activity, such as extended half-lives in vivo due to resistance to metabolic breakdown, or protease activity. Furthermore, it is well known that in certain systems constrained peptides show enhanced functional activity (Hruby (1982) Life Sciences 31:189-199 and Hruby et al. (1990) Biochem J. 268:249-262); the present disclosure provides a method to produce a constrained peptide that incorporates random sequences at all other positions.

Non-classical amino acids may be incorporated in the peptides of the disclosure in order to introduce particular conformational motifs, examples of which include without limitation: 1,2,3,4-tetrahydroisoquinoline-3-carboxylate (Kazrnierski et al. (1991) J. Am. Chem. Soc. 113:2275-2283); (2S,3S)-methyl-phenylalanine, (2S,3R)-methyl-phenylalanine, (2R,3S)-methyl-phenylalanine and (2R,3R)-methyl-phenylalanine (Kazmierski & Hruby (1991) Tetrahedron Lett. 32(41):5769-5772); 2-aminotetrahydronaphthalene-2-carboxylic acid (Landis (1989) Ph.D. Thesis, University of Arizona); hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (Miyake et al. (1989) J. Takeda Res. Labs. 43:53-76) histidine isoquinoline carboxylic acid (Zechel et al. (1991) Int. J. Pep. Protein Res. 38(2):131-138); and HIC (histidine cyclic urea), (Dharanipragada et al. (1993) Int. J. Pep. Protein Res. 42(1):68-77) and (Dharanipragada et al. (1992) Acta. Crystallogr. C. 48:1239-1241).

The following amino acid analogs and peptidomimetics may be incorporated into a peptide to induce or favor specific secondary structures: LL-Acp (LL-3-amino-2-propenidone-6-carboxylic acid), a β-turn inducing dipeptide analog (Kemp et al. (1985) J. Org. Chem. 50:5834-5838); β-sheet inducing analogs (Kemp et al. (1988) Tetrahedron Lett. 29:5081-5082); β-turn inducing analogs (Kemp et al. (1988) Tetrahedron Lett. 29:5057-5060); α-helix inducing analogs (Kemp et al. (1988) Tetrahedron Lett. 29:4935-4938); α-turn inducing analogs (Kemp et al. (1989) J. Org. Chem. 54:109:115); analogs provided by the following references: Nagai & Sato (1985) Tetrahedron Lett. 26:647-650; and DiMaio et al. (1989) J. Chem. Soc. Perkin Trans. p. 1687; a Gly-Ala turn analog (Kahn et al. (1989) Tetrahedron Lett. 30:2317); amide bond isostere (Clones et al. (1988) Tetrahedron Lett. 29:3853-3856); tetrazole (Zabrocki et al. (1988) J. Am. Chem. Soc. 110:5875-5880); DTC (Samanen et al. (1990) Int. J. Protein Pep. Res. 35:501:509); and analogs taught in Olson et al. (1990) J. Am. Chem. Sci. 112:323-333 and Garvey et al. (1990) J. Org. Chem. 56:436. Conformationally restricted mimetics of beta turns and beta bulges, and peptides containing them, are described in U.S. Pat. No. 5,440,013.

It is known to those skilled in the art that modifications can be made to any peptide by substituting one or more amino acids with one or more functionally equivalent amino acids that does not alter the biological function of the peptide. In one aspect, the amino acid that is substituted by an amino acid that possesses similar intrinsic properties including, but not limited to, hydrophobicity, size, or charge. Methods used to determine the appropriate amino acid to be substituted and for which amino acid are know to one of skill in the art. Non-limiting examples include empirical substitution models as described by Dahoff et al. (1978) In Atlas of Protein Sequence and Structure Vol. 5 suppl. 2 (ed. M. O. Dayhoff), pp. 345-352. National Biomedical Research Foundation, Washington D.C.; PAM matrices including Dayhoff matrices (Dahoff et al. (1978), supra, or JTT matrices as described by Jones et al. (1992) Comput. Appl. Biosci. 8:275-282 and Gonnet et al. (1992) Science 256:1443-1145; the empirical model described by Adach & Hasegawa (1996) J. Mol. Evol. 42:459-468; the block substitution matrices (BLOSUM) as described by Henikoff & Henikoff (1992) Proc. Natl. Acad. Sci. USA 89:1-1; Poisson models as described by Nei (1987) Molecular Evolutionary Genetics. Columbia University Press, New York.; and the Maximum Likelihood (ML) Method as described by Müller et al. (2002) Mol. Biol. Evol. 19:8-13.

RNAi or siRNA

A siRNA can be designed following procedures known in the art. See, e.g., Dykxhoorn, D. M. and Lieberman, J. (2006) “Running Interference: Prospects and Obstacles to Using Small Interfering RNAs as Small Molecule Drugs,” Annu. Rev. Biomed. Eng. 8:377-402; Dykxhoorn, D. M. et al. (2006) “The silent treatment: siRNAs as small molecule drugs,” Gene Therapy, 13:541-52; Aagaard, L. and Rossi, J. J. (2007) “RNAi therapeutics: Principles, prospects and challenges,” Adv. Drug Delivery Rev. 59:75-86; de Fougerolles, A. et al. (2007) “Interfering with disease: a progress report on siRNA-based therapeutics,” Nature Reviews Drug Discovery 6:443-53; Krueger, U. et al. (2007) “Insights into effective RNAi gained from large-scale siRNA validation screening,” Oligonucleotides 17:237-250; U.S. Patent Application Publication No. 2008/0188430; and U.S. Patent Application Publication No. 2008/0249055.

siRNAs can be made with methods known in the art. See, e.g., Dykxhoorn, D. M. and Lieberman, J. (2006) “Running Interference: Prospects and Obstacles to Using Small Interfering RNAs as Small Molecule Drugs,” Annu. Rev. Biomed. Eng. 8:377-402; Dykxhoorn, D. M. et al. (2006) “The silent treatment: siRNAs as small molecule drugs,” Gene Therapy, 13:541-52; Aagaard, L. and Rossi, J. J. (2007) “RNAi therapeutics: Principles, prospects and challenges,” Adv. Drug Delivery Rev. 59:75-86; de Fougerolles, A. et al. (2007) “Interfering with disease: a progress report on siRNA-based therapeutics,” Nature Reviews Drug Discovery 6:443-53; Krueger, U. et al. (2007) “Insights into effective RNAi gained from large-scale siRNA validation screening,” Oligonucleotides 17:237-250; U.S. Patent Application Publication No. 2008/0188430; and U.S. Patent Application Publication No. 2008/0249055.

A siRNA may be chemically modified to increase its stability and safety. See, e.g., Dykxhoorn, D. M. and Lieberman, J. (2006) “Running Interference: Prospects and Obstacles to Using Small Interfering RNAs as Small Molecule Drugs,” Annu. Rev. Biomed. Eng. 8:377-402 and U.S. Patent Application Publication No. 2008/0249055.

Antibody Compositions

The disclosure, in another aspect, provides an antibody that binds an isolated polypeptide of the disclosure. The antibody can be a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a humanized antibody or a derivative or fragment thereof as defined below. In one aspect, the antibody is detectably labeled or further comprises a detectable label conjugated to it.

Also provided is a composition comprising the antibody and a carrier. Further provided is a biologically active fragment of the antibody, or a composition comprising the antibody fragment. Suitable carriers are defined supra.

Further provided is an antibody-peptide complex comprising, or alternatively consisting essentially of, or yet alternatively consisting of, the antibody and a polypeptide specifically bound to the antibody. In one aspect, the polypeptide is the polypeptide against which the antibody is raised.

This disclosure also provides an antibody capable of specifically forming a complex with a protein or polypeptide of this disclosure, which are useful in the therapeutic methods of this disclosure. The term “antibody” includes polyclonal antibodies and monoclonal antibodies, antibody fragments, as well as derivatives thereof (described above). The antibodies include, but are not limited to mouse, rat, and rabbit or human antibodies. Antibodies can be produced in cell culture, in phage, or in various animals, including but not limited to cows, rabbits, goats, mice, rats, hamsters, guinea pigs, sheep, dogs, cats, monkeys, chimpanzees, apes, etc. The antibodies are also useful to identify and purify therapeutic polypeptides.

Combination Therapy

The compositions and related methods of the present invention may be used in combination with the administration of other antitumor therapies. These include, but are not limited to, the administration of chemotherapy, surgery, and/or radiation.

The additional therapeutic treatment can be added prior to, concurrent with, or subsequent to methods or compositions described herein, and can be contained within the same formulation or as a separate formulation.

Screening Assays

The present invention provides methods or in vitro screening assays for screening candidate agents to identify a potential therapeutic agent of inhibiting tumor growth or for tumor suppression, comprising contacting a candidate agent with VprBP, initiating a kinase reaction, wherein the agent is a potential therapeutic agent if a reduction of kinase activity as compared to the kinase activity of VprBP in the absence of the agent is observed.

Kits

Also provided are kits comprising, or alternatively consisting essentially of, or yet further consisting of, a polynucleotide, a polypeptide or compound of this disclosure and optionally, instructions for use in the therapeutic, diagnostic and/or screening methods disclosed herein.

Experimental Experiment No. 1

Histone modifications play important roles in the regulation of gene expression and chromatin organization. VprBP has been implicated in transcriptionally silent chromatin formation and cell-cycle regulation, but the molecular basis underlying such effects remains unclear. Here Applicants report that VprBP possesses an intrinsic protein kinase activity and is capable of phosphorylating histone H2A on threonine 120 (H2AT120p) in a nucleosomal context. VprBP is localized to a large set of tumor suppressor genes and blocks their transcription, in a manner that is dependent on its kinase activity toward H2AT120. The functional significance of VprBP-mediated H2AT120p is further underscored by the fact that RNAi knockdown and small-molecule inhibition of VprBP reactivate growth regulatory genes and impede tumor growth. Applicants' findings establish VprBP as a major kinase responsible for H2AT120p in cancer cells and suggest that VprBP inhibition could be a new strategy for the development of anticancer therapeutics.

The formation of silent chromatin plays important roles in the regulation of gene expression and maintenance of chromosome stability in eukaryotes. Inactive chromatin domains are often associated with distinct histone modifications (Suganuma, T. et al. (2011) Annu. Rev. Biochem. 80:473-499). Like other histone modifications, histone phosphorylation has been linked to various cellular processes such as transcriptional regulation and DNA repair (Banerjee, T. et al. (2011) Mol. Cell. Biol. 31:4858-4873). Histone phosphorylation can occur on serine, threonine, and tyrosine residues and constitutes a part of the signal to influence chromatin structure and factor recruitment. For example, phosphorylations of H3S10, H3S28, and H2B S32 are linked to the expression of proto-oncogenes such as c-fos, c-jun, and c-myc (Choi, H. S. et al. (2005) Cancer Res. 65:5818-5827; Lau, A. T. et al. (2011) J. Biol. Chem. 286:26628-26637; Lau, P. N. et al. (2011) Proc. Natl. Acad. Sci. USA 108:2801-2806). Phosphorylations of H3S10, H3T11, and H3 S28 play a role in combination with H3 acetylation in transcription activation and cell proliferation (Gehani, S. S. et al. (2010) Mol. Cell 39:886-900; Lau, P. N. et al. (2011) Proc. Natl. Acad. Sci. USA 108:2801-2806; Lo, W. S. et al. (1998) J. Mol. Biol. 276:19-42; Shimada, M. et al. (2008) Cell 132:221-232; Yang, W. et al. (2012) Cell 150:685-696). Conversely, H2AS1 phosphorylation inhibits chromatin transcription, and H3 preacetylation interferes with this repressive modification (Zhang, Y. et al. (2004) J. Biol. Chem. 279:21866-21872). In some cases, histone phosphorylation facilitates nucleosome binding by proteins containing phospho-binding modules and restricts their activity as downstream effectors around a specific region. While a large number of phosphorylation sites have been identified in core histones, the identification of kinases responsible for these modifications remains an area of intensive investigation. VprBP is a large nuclear protein that can interact with HIV viral protein R and Cullin 4-DDB 1 ubiquitin ligase complex (Li, W. et al. (2010) Cell 140:477-490). The cellular function of VprBP has been studied mainly with respect to its role in regulating Cullin 4 E3 ubiquitin ligase activity and cell-cycle progression (Hrecka, K. et al. (2007) Proc. Natl. Acad. Sci. USA 104:11778-11783; McCall, C. M. et al. (2008) Mol. Cell. Biol. 28, 5621-5633). However, more recent studies have implicated VprBP in a much wider range of cellular processes, as exemplified by its engagement in JNK-mediated apoptosis during cellcompetition process (Tamori, Y. et al. (2010) PLoS Biol. 8:e1000422). Another striking example is the demonstration made by us that VprBP acts as an effector that binds histone H3 tails protruding from nucleosomes and establishes chromatin silencing in cancer cells (Kim, K. et al. (2012) Mol. Cell. Biol. 32:783-796). These results clearly indicate that VprBP plays a negative regulatory role in transcription, but precisely how VprBP mediates its effects on the formation of repressive chromatin domain is poorly understood.

Here Applicants report that VprBP has an intrinsic kinase activity and phosphorylates histone H2A at threonine 120. Functional studies reveal that H2AT120p by VprBP is sufficient to repress chromatin transcription. RNA interference (RNAi)-mediated knockdown of VprBP impairs H2AT120p, transactivates a large set of tumor suppressor genes, and inhibits cell proliferation. Furthermore, using a highly potent and selective inhibitor for VprBP, Applicants show that downregulation of VprBP-mediated H2AT120p impedes cancer cell proliferation and xenograft tumor progression.

Results VprBP Possesses Kinase Activity and Phosphorylates Threonine 120 of Histone H2A

Given that dysregulation of histone-modifying activities is linked to human cancers (Chi, P. et al. (2010) Nat. Rev. Cancer 10:457-469; Dawson, M. A. et al. (2012) Cell 150:12-27), Applicants reasoned that VprBP expression in cancer cells might influence specific histone modifications. As expected, western blotting of cell lysates confirmed that VprBP is expressed highly in DU145 prostate, LD611 bladder, and MDA-MB231 breast cancer cell lines but minimally in their corresponding normal counterparts (FIGS. 1A and 5A). In exploring whether any histone modifications are altered in the cancer cell lines, Applicants detected much higher levels of H2AT120p in chromatin fractions. To assess the relationship between VprBP expression and H2AT120p more directly, Applicants examined a possible effect of VprBP depletion. Upon the stable knockdown of VprBP, the abundant H2AT120p found in the cancer cell lines was drastically reduced, but changes in other modifications were much less pronounced or absent (FIGS. 1B and 5B).

The data above suggest that VprBP may be of particular importance for H2AT120p reactions in cancer cells. To test this possibility, Applicants incubated free individual histones with [g-32P]-ATP and recombinant VprBP produced in baculovirus-infected insect cells. The integrity and purity of the VprBP protein were confirmed by silver-stained SDS-PAGE (FIG. 5C) and mass spectrometry (FIG. 5D). Autoradiograph of the kinase reaction products showed a robust phosphorylation of H2A, but not other core histones (FIG. 1C). Expectedly, VprBP showed no enzymatic activity in our in vitro HAT and HMT assays (FIG. 5E). As the core histones exist within nucleosomes in the cell nucleus, kinase assays were repeated with nucleosomes reconstituted from recombinant histones and the 601 nucleosome positioning sequence (Lowary, P. T. et al. (1998) J. Mol. Biol. 276:19-42). VprBP generated clear labeling of H2A in the nucleosome after autoradiography (FIG. 5F). These results were further corroborated by in vitro kinase assays with nucleosomes immobilized on agarose beads (FIG. 5G) and with VprBP immunoaffinity purified from DU145 cell lysates (FIG. 5H). In additional support, the in-gel autophosphorylation assays showed a phosphorylated band at the expected molecular weight of VprBP (FIG. 5I).

Consistent with these findings, sequence alignments with CK1 and Mut9p kinases identified 8 out of the 12 protein kinase subdomains (Hanks, S. K. et al. (1988) Science 241:42-52; Taylor, S. S. et al. (1992) Annu. Rev. Cell Biol. 8:429-462) in the N-terminal region of VprBP (FIG. 1D, residues 141-500). The lysine residue in the subdomain II is critical for kinase enzymatic activity (Casas-Mollano, J. A. et al. (2008) Proc. Natl. Acad. Sci. USA 105:6486-6491; Zhai et al., 1992). VprBP does not have this conserved residue in its subdomain II but has lysine 194 immediately adjacent to the subdomain II. Notably, mutation of this lysine residue completely abrogated kinase activity (FIG. 1E, lanes 1 and 2; FIG. 5J, lanes 1 and 2). Mutation at either D361 or K363 that is conserved in the subdomain VI also impaired the catalytic activity (FIG. 1E, lanes 3 and 4; FIG. 5J, lanes 3 and 4). On the contrary, mutation of L378 lying outside the conserved subdomains did not affect VprBP kinase activity (FIG. 1E, lane 6; FIG. 5J, lane 5). These results exclude the possibility that the observed H2AT120p is due to a contaminating kinase in the preparation of recombinant VprBP. All VprBP mutants exhibited circular dichroism spectra almost identical to those of the wild-type VprBP (FIG. 5K), thus ruling out the possibility that the altered structure of the VprBP mutants is responsible for their reduced kinase activity.

In determining VprBP phosphorylation sites in H2A, Applicants found that simultaneous deletion of the N- and C-terminal tails of H2A blocks H2A phosphorylation by VprBP (FIG. 1F, lanes 1-4). Moreover, VprBP-mediated phosphorylation is completely abolished by mutation of T120, whereas mutations of six other potential modification sites on the tail domains had little effect (lanes 5-14). Western blot analysis of the kinase reactions using anti-H2AT120p antibody further confirmed that VprBP stimulates the phosphorylation of H2AT120 in the nucleosome (FIG. 1G).

VprBP-Mediated H2AT120p is Highly Abundant in Tumors and Necessary for Cancer Cell Proliferation

To decipher the clinical significance of VprBP-mediated H2AT120p, Applicants next analyzed the levels of VprBP and H2AT120p in multiple patient-matched normal and tumor tissue microarray (FIG. 2A; Table 1). Immunohistochemical analysis on 16 types of organ cancer with matched adjacent normal tissue demonstrated a clear link between elevated expression of VprBP and increased levels of H2AT120p in more than 70% of the tumor samples. This trend was more evident in bladder, breast, and prostate tumor samples. In cases where there was no change in VprBP expression, the same trend was observed for H2AT120p. These findings validate the results from cell lines and support the conjecture that VprBP possesses oncogenic properties and its kinase activity contributes to the observed changes. To address this issue, Applicants tested the effects of VprBP depletion on the proliferation of DU145 cancer cells. Expectedly, much lower levels of VprBP were detected in VprBP-depleted cells compared to mock-depleted cells, and the observed reduction of VprBP correlated well with decreased H2AT120p (FIGS. 2B and 6A). MTT assays over a 5-day time course also revealed that VprBP depletion gradually decreased the viability of cancer cells and that the expression of VprBP wildtype, but not VprBP K194R kinase-dead mutant, restored H2AT120p and cell proliferation rates (FIGS. 2C and 6B). Analogously, VprBP depletion interfered with cell proliferation and thus reduced the number of colony-forming cells; colony numbers increased to about 75% of undepleted cells after the expression of wild-type but not K194R-mutated VprBP in the depleted cells (FIGS. 2D and 6C). Consistent with these observations, VprBP overexpression in MLC cells containing low levels of VprBP increased H2AT120p, thereby facilitating cell proliferation and colony formation (FIGS. 6D-6F).

VprBP-Mediated H2AT120p Inactivates Cell Growth Regulatory Genes

As VprBP has been reported to act as a negative regulator of chromatin transcription (Kim, K. et al. (2012) Mol. Cell. Biol. 32:783-796), Applicants sought to determine whether H2AT120p is required for VprBP function. In the absence of VprBP, high levels of transcription from chromatin reconstituted from G5ML-601 array DNA and recombinant histones were achieved by Gal4-VP16 and p300 (FIG. 3A, lanes 1 and 2). When chromatin was phosphorylated by VprBP, significant repression of transcription was evident (lanes 3 and 4). Intriguingly, however, the ability of VprBP to block transcription was compromised upon mutation of H2AT120 in chromatin (lanes 9 and 10) or omission of ATP from the reaction (FIG. 7A). Furthermore, addition of VprBP kinase-dead mutant to transcription reactions had no detectable effect on transcription (FIG. 3A, lanes 5, 6, 11, and 12), strongly arguing that H2AT120p is the cause of the observed repression.

Next, Applicants performed comprehensive microarray analysis with total RNA isolated from mock- or VprBP-depleted DU145 cancer cells. With a fold-change cutoff of >1.7 and stringent p<0.005, the gene expression profiling showed that 292 genes were activated and 208 genes were repressed (FIG. 3B; Tables 2 and 3) in response to VprBP knockdown. Many of the genes upregulated upon VprBP depletion encode cell proliferation and growth regulators (FIG. 7B), including those known to be key regulatory components for cancer initiation and progression (FIG. 3C). The transcriptional changes detected by microarray were validated by qRT-PCR of eight genes whose expression was increased upon VprBP depletion, and one unaffected control gene (FIG. 3D). To check whether the candidate target genes harbor VprBP and H2AT120p, Applicants conducted ChIP assays. In mock-depleted cells, VprBP occupied the promoter and coding regions of the target genes, and H2AT120p showed similar distribution across the loci (FIGS. 3E and 7C). Consistent with previous studies (Schones, D. E. et al. (2008) Cell 132:887-898), nucleosomes are depleted in the vicinity of a transcription start site (TSS), as indicated by the low levels of H2A and H3. For this reason, ChIP analysis exhibited low levels of VprBP and H2AT120p over the TSS of the target genes. Importantly, VprBP depletion resulted in greatly reduced levels of VprBP and concomitant loss of H2AT120p at the candidate target genes, reinforcing the conclusion that H2AT120p observed in these genes is dependent of VprBP. In the case of the RARRES1 gene, which is not affected by VprBP knockdown (FIG. 3D), the H2AT120p levels were low and remained unchanged under control and VprBP knockdown conditions (FIG. 7C).

B32B3 is a Potent and Selective Inhibitor of VprBP and Suppresses Tumor Growth

The fact that VprBP knockdown abrogates H2AT120p and slows cancer cell growth prompted us to look for highly potent and selective inhibitors for VprBP. To this end, Applicants' inhouse small-molecule library of 5,000 compounds was screened. When the inhibitory potential of the compounds was assessed by in vitro kinase assays, two of them (0.002% hit rate), designated as B32B3 and B20H6, inhibited VprBP and decreased H2AT120p at a concentration of 5 mM (FIG. 4A). To evaluate their cellular effects, DU145 cells were treated with the compounds in the concentration range of 0-5 mM for 24 hr. B32B3 potently inhibited H2AT120p with a half-maximal inhibitory concentration (IC50) value of 0.5 mM, as evaluated by western blotting and immunostaining (FIGS. 4B, 4D, and 8A). The observed reduction in H2AT120p was paralleled by inhibition of cell proliferation (FIGS. 4E and 8B). By comparison, B20H6 failed to produce any detectable changes in H2AT120p and cell growth after treatment (FIG. 4B, lanes 7-12; and FIG. 8B), suggesting that this compound might be relatively unstable with poor cellular uptake. Importantly, the knockdown of VprBP sensitized DU145 cells to B32B3 with a circa 2-fold decrease in the IC50, whereas B32B3 was considerably less potent in DU145 cells overexpressing VprBP (FIG. 8A). Furthermore, B32B3 treatment at concentrations up to 5 mM minimally antagonized the proliferation of MLC cells lacking VprBP-mediated H2AT120p (FIGS. 8C and 8D). These results indicate that B32B3 preferentially targets cancer cells exhibiting high levels of VprBP and H2AT120p. That the IC50 value of B32B3 was increased in the presence of incremental concentrations of ATP argues strongly that B32B3 competes with ATP and may bind to the kinase active site (FIG. 8E). Additionally, when tested against a panel of 33 human kinases, B32B3 showed greater than 100-fold selectivity for VprBP over 33 other kinases with an IC50 of 0.6 mM (Table 4). Thus, although Applicants cannot exclude the possibility that other kinases that were not included in the selectivity screen might be affected, B32B3 can be defined as a highly specific VprBP inhibitor at present.

A key question that arises from our findings is whether B32B3 exhibits antitumor efficacy through its VprBP inhibitory activity. To address this question, Applicants inoculated 1 3 107 DU145 cancer cells into nude mice and treated tumor xenografts with intraperitoneal injections of B32B3 at a dose of 5 mg/kg twice a week over 3 weeks. Tumor growth was inhibited, as calculated the day after the last treatment of B32B3, by 70%-75% (FIGS. 4F and 4G). At these doses, B32B3 appeared to be well tolerated in mice, and it did not cause any significant weight loss during treatment (FIG. 8F). In evaluating the pharmacokinetic properties of B32B3, Applicants found that B32B3 has a half-life of approximately 7 hr in mouse plasma and a Cmax of 1 mM at a dose of 5 mg/kg in mice (FIGS. 8G and 8H). To correlate B32B3 antitumor activity with VprBP inhibition, DU145 xenograft tumors explanted from DMSO- or B32B3-treated mice were analyzed by immunohistochemistry. The levels of H2AT120p were greatly decreased in the tumors of B32B3-treated mice, compared to DMSO-treated controls (FIG. 4H). To elucidate the mechanistic basis of the B32B3 effects, Applicants tested if the compound could rescue the transcriptional inhibition caused by VprBP. As summarized in FIG. 4I, treatment of DU145 cells with B32B3 (1 mM) resulted in, albeit to a varying extent, higher expression of VprBP target genes. Because H2AT120p is essential for VprBP transrepression, Applicants also examined the effects of B32B3 on H2AT120p at the target genes. VprBP was present at high levels at both promoter and coding regions, which did not alter upon B32B3 treatment. However, H2AT120p at the regions was reduced by 70%, following B32B3 treatment at the same dose (FIGS. 4J and 8I). B32B3 thus displays anticancer properties at least in part, by interfering with VprBP-mediated H2AT120p at the target genes.

DISCUSSION

This work describes the systematic biochemical and cellular analysis of VprBP and unveils a surprising mechanism underlying the formation of repressive chromatin by VprBP. A key finding is that the N-terminal region of VprBP possesses a previously unrecognized kinase activity for H2AT120. VprBP contains 8 out of the 12 conserved protein kinase subdomains, and mutations of these subdomains abolish the catalytic activity, further confirming that VprBP is a bona fide protein kinase. Interestingly, while most histone kinases identified so far are incapable of phosphorylating nucleosomal histones, VprBP displays an unusual additional activity as an effective kinase of nucleosomes. In this respect, VprBP resembles Drosophila NHK-1, which catalyzes phosphorylation of H2AT119 (equivalent to human H2AT120) in the nucleosomal context (Aihara, H. et al. (2004) Genes Dev. 18:877-888). It has been reported that Bub1 acts as a centromere-specific kinase for H2AS121 (H2AT120 in human) during prometaphase and metaphase in fission yeast (Kawashima, S. A. et al. (2010) Science 327:172-177). Applicants' attempts to detect any significant changes in H2AT120p in Bub1-depleted DU145 cells have been unsuccessful (FIG. 5L), probably because Applicants have used unsynchronized interphase cells. Applicants also observed that Bub1 is expressed at similar levels in MLC normal and DU145 cancer cells (FIG. 5M). It thus appears that the role of VprBP-mediated H2A phosphorylation is distinct from that of Bub1-mediated H2A phosphorylation. Further structural and biological analyses of VprBP and Bub1 would be helpful for understanding the functional differences of these two kinases.

There has been no demonstration that H2AT120p is involved in the regulation of gene expression, although recently this possibility has been discussed. Our well-defined in vitro assay system allows us to provide the first direct connection between H2AT120p and transcriptional repression. Importantly, blocking VprBP-mediated H2AT120p by point mutation, Applicants have been able to verify that H2AT120p is a critical determinant of repressive action of VprBP. In accord with these in vitro data, gene expression profiling demonstrated that VprBP downregulates 292 genes, many of which are involved in cell proliferation and programmed cell death. An intriguing question raised by these results is how H2AT120p by VprBP modulates chromatin transcription. One possible mechanism is that H2AT120p can affect the occurrence of other histone modifications on the same or different histone tails. Recent work from our lab has shown that VprBP interacts with HDAC1, thereby inhibiting H3 acetylation at p53 target genes (Kim, K. et al. (2012) Mol. Cell. Biol. 32:783-796). This suggests that H2AT120p at target genes may influence HDAC1 activity required for gene repression. Another possibility is that H2AT120p could serve as an integrating platform for repressor proteins. Considering the fact that the centromere cohesion protector shugoshin recognizes H2AT120p and recruits heterochromatin protein Swi6/HP1 at centromeres in fission yeast (Kawashima, S. A. et al. (2010) Science 327:172-177; Yamagishi, Y. et al. (2008) Nature 455:251-255), the recruitments of factors to specific chromatin domains are likely to be part of the mechanisms for VprBP-induced gene silencing. Another question unsolved in our study is how VprBP is initially localized at target genes. A likely model is that VprBP physically associates with gene specific factors to influence the transcription of target genes, as supported by our recent finding that VprBP-p53 interaction is a key event in VprBP action on p53 target genes (Kim, K. et al. (2012) Mol. Cell. Biol. 32:783-796). Thus, more extensive studies of VprBP interaction with DNA-binding factors and other coregulators would provide a molecular explanation to gene-specific function of VprBP.

VprBP expression is significantly higher in breast, bladder, and prostate cancer tissues compared to their benign counterparts. The observation that VprBP knockdown significantly decreased H2AT120p and cancer cell growth indicates that VprBP could be an ideal target for cancer therapy. As the first step toward checking this possibility, Applicants screened large numbers of compounds in a high-throughput manner and identified B32B3 as a selective inhibitor of VprBP. B32B3 is thought to inhibit VprBP kinase activity by competing with ATP. Importantly, B32B3 recapitulates the most molecular phenotypes that arise from VprBP knockdown: (1) the reduction of H2AT120p at target genes, (2) higher expression of VprBP target genes, and (3) the impairment of cancer cell growth. Thus, B32B3 represents a unique tool to investigate the regulatory pathways governing H2AT120p in physiological and tumorigenic conditions. Moreover, the selectivity for cancer cells in culture and our ability to demonstrate efficacy in a mouse model of VprBP at doses that were well tolerated suggest that inhibition of VprBP by B32B3 may provide a pharmacological basis for therapeutic intervention against cancers.

Experimental Procedures In Vitro Kinase and Transcription Assays

Recombinant mononucleosomes and nucleosome arrays were reconstituted using recombinant histone octamers as recently described (Jaskelioff, M. et al. (2000) Mol. Cell. Biol. 20:3058-3068; Robinson, P. J. et al. (2008) J. Mol. Biol. 381:816-825). For kinase assays, recombinant VprBP was incubated with free histones (1 mg) or reconstituted nucleosomes (2 mg) in kinase buffer (50 mM Tris-HCl [pH 7.5], 20 mM EGTA, 10 mM MgCl2, 1 mM DTT, and 1 mM b-glycerophosphate) containing 10 mCi of [g-32P] ATP and 4 mM ATP for 30 min at 30_C. Proteins from each reaction were separated by SDS-PAGE, Coomassie blue stained, dried, and visualized by autoradiography. To create VprBP inhibitors, a collection of 5,000 compounds was screened in the same kinase assays at a final concentration of 5 mM. The selectivity of B32B3 toward VprBP kinase was assessed in a panel of 33 kinases listed in Table 4. In vitro transcription assays were as described (Kim, K. et al. (2012) Mol. Cell. Biol. 32:783-796), except that G5ML-601 nucleosome arrays (100 ng) and Gal4-VP16 (15 ng) were used for the reactions. Recombinant VprBP (25 or 50 ng) and ATP (10 mM) were added before p300 (20 ng) and AcCoA (10 mM).

Mice Xenografts

All animal experiments were performed according to protocols approved by the Institutional Animal Care and Use Committee. Tumor xenografts were established by subcutaneous injection of 1 3 107 DU145 cells into 8-weekold female nude mice (n=8). At day 5 after injection, the mice bearing DU145 tumor xenografts were treated with twice-weekly i.p. injections of either DMSO or B32B3 at a dose of 5 mg/kg throughout the duration of the experiment. Tumor dimension was measured by calipers twice a week, and tumor mass was calculated as described (Heo, K. et al. (2012) Oncogene 32:2510-2520). The mice were killed by asphyxiation with CO2, and tumors were excised and weighed 25 day after the cell injection. To analyze the H2AT120p, formalin-fixed and paraffin-embedded sections (5 mm) from DU145 tumor xenografts were subject to immunohistochemistry. Animal studies were conducted under approved institutional protocols.

Accession Numbers

The NCBI GEO accession number for microarray data reported in this application is GSE50414.

Cell Culture, Constructs and Antibodies

MDA-MB231, LD611 and DU145 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS. MCF-10-2A cells were grown in a 1:1 mixture of DMEM and Ham's F12 supplemented with 20 ng/ml epidermal growth factor, 100 ng/ml cholera toxin, 0.01 mg/ml insulin, 500 ng/ml hydrocortisone, and 5% horse serum. Urotsa cells were grown in DMEM low glucose containing 10% FBS. MLC cells were grown in T medium containing 10% FBS. To express VprBP using the baculovirus system, VprBP cDNA was subcloned into the EcoRI and XhoI sites of pFASTBAC vector with an N-terminal His epitope. To generate VprBP mutants, VprBP cDNA was mutated by the QuikChange® II site-directed mutagenesis kit (Agilent Technologies) before the construction. For mammalian expression of VprBP wild type and mutants, the corresponding cDNAs were amplified by PCR and ligated into the EcoRI and SalI sites of lentiviral expression vector pLenti-Hygro (addgene) containing 5′ FLAG coding sequence. For bacterial expression of human H2A proteins, H2A cDNA was inserted into the NdeI and BamHI sites of pET-11a or pET-11d vector in frame with FLAG sequences. Single- or multiple-residue substitutions in H2A were made by QuickChange kit and verified by DNA sequencing. Antibodies specific for H3ac, H4ac, H2Aac, H2Bac, H3K27me3, H3S10p and H2A were from Millipore; antibodies for H3K4me3, H3K9me3 and H2AT120p (for Western blotting) were from Active Motif; antibodies for H3K36me3 and H2AT120p (for immunostaining and ChIP) were from Abcam; antibody for VprBP was from Proteintech Group; antibody for Bub1 was from GeneTex; and antibody for actin was from Sigma.

Chromatin Extraction

Cells were lyzed by suspending in buffer A (10 mM HEPES, pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM DTT, 5 mM β-glycerophosphate, 10 mM NaF, protease inhibitor, and 0.2% TritonX-100) and incubating on ice for 8 min. Nuclei were isolated by centrifugation (1,300×g for 10 min at 4° C.), and the supernatant was discarded. The resulting nuclei pellet was resuspended in buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 5 mM β-glycerophosphate, 10 mM NaF, and protease inhibitor) and incubated for 30 min on ice. The suspension was centrifuged (1,700×g for 5 min at 4° C.) and then the pellet was washed with buffer B three times. The chromatin pellet was sonicated in Laemli sample buffer.

Recombinant Proteins

His-VprBP wild type and mutants were expressed using a baculovirus vector in insect (Sf9) cells. The expressed proteins were initially purified with Ni-NTA agarose (Novagen), and further purified with Q Sepharose (GE healthcare) column according to standard procedures. The purity and intactness of the recombinant VrpBP proteins were confirmed by quantitative LC-MS/MS and Western blotting. Recombinant histones were expressed in Escherichia coli Rosetta 2 (DE3) pLysS cells (Novagen) and purified as described previously (Dyer, P. N. et al. (2004) Methods Enzymol. 375:23-44).

In-Gel Kinase Assay

In-gel kinase assay was performed as described (Wooten, M. W. (2002) Sci. STKE 2002:115) with minor modifications. Briefly, wild type and mutant VprBP proteins (5 μg) were resolved on an 8% SDS-PAGE gel, and the VprBP proteins in the gel were denatured in denaturation buffer (50 mM Tris-HCl, pH 8.0, 20 mM DTT and 6 M Guanidine HCl) for 1 h at room temperature and were renatured for 16 h at 4° C. in renaturation buffer (50 mM Tris-HCl, pH 8.0, 5 mM DTT, 0.04% Tween-20, 100 mM NaCl and 5 mM MgCl2). The kinase reaction was initiated in 15 ml of kinase buffer (25 mM Hepes, pH 7.4, 20 mM MgCl2, 5 mM NaF, 1 mM DTT) containing 50 μM ATP and 20 Ci of [γ-32P] ATP for 1 h at 30° C. The reaction was terminated by washing the gel with a fixing solution containing 10 mM sodium pyrophosphate and 5% trichloroacetic acid for 2 h. The gel was dried and subjected to autoradiography.

Circular Dichroism (CD) Spectroscopy

CD measurements were recorded using a Jasco J-810 spectropolarimeter with a 0.1 cm pathlength cuvette and a protein concentration of 1 μM. Circular dichroism spectra were obtained at 25° C. in phosphate buffer (10 mM sodium phosphate and 50 mM NaCl, pH 7.4). For each sample, 20 scans from 200 to 260 nm were averaged.

Immunostaining

The levels of VprBP and H2AT120p in tumors tissues were determined in FDA human tumor organ tissue microarray, which includes 16 types of organ cancer with matched or unmatched adjacent normal tissue (US Biomax, Inc). The formalin-fixed, paraffin-embedded sections were blocked by treating with blocking reagent (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.3% Triton X-100, and 5% normal goat serum) for 30 min at room temperature and incubated with VprBP and H2AT120p antibodies at 4° C. overnight. Immunodetection was performed using ABC reagent (Vectorstain). DAB (Vector Lab) was used for color development and hematoxylin (Sigma) was used for counterstaining. The intensity and distribution patterns of staining were evaluated by semiquantitative immunohistochemical assessment. The intensity of staining was graded from − to +++ (−, no staining; +, weak staining; ++, moderate staining; and +++, strong staining). The distribution of staining was classified from 0 to 3 (0, 0-20%; 1, 21-50%; 2, 51-80%; 3, 81-100%). For immunofluorescence of DU145 cells, cells were treated with DMSO or B32B3 (0.5 μM) for 24 h and fixed with 4% paraformaldehyde for 15 min. The corresponding samples were permeabilized with 0.3% Triton X-100 for 15 min and immunostained with H2AT120p antibody.

RNA Interference

DNA oligonucleotides encoding VprBP shRNA1 (5′-CGAGAAACTGAGTCAAATGAA-3′) (SEQ ID NO: 1), VprBP shRNA2 (5′-AATCACAGAGTATCTTAGA-3′) (SEQ ID NO: 2) and Bub1 shRNA (5′-CGAGGTTAATCCAGCACGTAT-3′) (SEQ ID NO: 3) were subcloned into pLKO.1-puro (Addgene) lentiviral vector according to standard procedures. To produce virus particles, 293T cells were cotransfected with the plasmids encoding VSV-G, NL-BH and the shRNAs. Two days after transfection, the soups containing the viruses were collected and used to infect cancer cells in the presence of polybrene (8 μg/ml).

Cell Proliferation and Colony Formation Assays

Cell proliferation was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as previously described (Kim, K. et al. (2012) Mol. Cell Biol. 32:783-796). To evaluate IC50 of compound B32B3 and B20H6, DU145 cells were treated with various concentrations (0.001, 0.005, 0.01, 0.05, 0.1, 1, 5, 10, and 20 μM) of compounds for 72 h and viability was measured by MTT assays. For soft agar colony formation assays, DU145 cells were treated with B32B3 (0.5, 1, and 3 μM). Cells were suspended in semisolid medium (DMEM 10% FBS plus 0.3% ultra pure noble agar) at concentrations of 2×10⁵ cells/ml, added over a layer of 0.6% agar in RPMI on 35 mm plate and incubated for an additional 21 days. The colonies in each well were stained with 0.005% crystal violet in 20% ethanol, counted and photographed. All assays were run in triplicate, and results presented are the average of three individual experiments.

Microarray and qRT-PCR

Total RNA was isolated from mock- or VprBP-depleted cells using the TRIzol reagent according to the manufacturer's instructions (Invitrogen). Gene expression microarray experiments were conducted using a whole-genome expression array (Human HT-12 v4 Expression BeadChip, Illumina). This high density oligonucleotide array chip targets more than 47000 probe sequences derived from National Center for Biotechnology Information Reference Sequence (NCBI) RefSeq Release 38 (Nov. 7, 2009) and other sources. Data were processed and analyzed by the ArrayPipe software (www.pathogenomics.ca/arraypipe). Genes whose expression level was increased or decreased by a factor of >1.7 after VprBP knockdown are listed in Tables 2 and 3. For qRT-PCR, total RNA was extracted as described for microarray and subjected to RT reactions with the use of PerfeCta® SYBR Green FastMix (Quanta BIOSCIENCES) and an iCycler IQ5 real time cycler (Bio-Rad). The specificity of the amplification reactions were monitored by melting curve analysis. Assays were normalized to β-actin mRNA levels. The following primers were used for qRT-PCR:

BMF  (5′-CTCAGCCGACTTCAGCTCTT-3′ (SEQ ID NO: 13) and 5′-AGCCAGCATTGCCATAAAAG-3′ (SEQ ID NO: 14)), NKX3-1 (5′-AGAAAGGCACTTGGGGTCTT-3′ (SEQ ID NO: 15) and 5′-TCCGTGAGCTTGAGGTTCTT-3′ (SEQ ID NO: 16)),  NOV (5′-ACGAGCTTTTGTCTCCGAAA-3′ (SEQ ID NO: 17) and 5′-ACACCAGACAGCATGAGCAG-3′ (SEQ ID NO: 18)), OPN3 (5′-GATCCCTTTTGCAGCTTCTG-3′ (SEQ ID NO: 19) and 5′-TTTGGACCCATTGGTTTTGT-3′ (SEQ ID NO: 20)),  SOCS2 (5′-AAAAGAGGCACCAGAAGGAA-3′ (SEQ ID NO: 21) and 5′-GTCCGCTTATCCTTGCACAT-3′ (SEQ ID NO: 22)),  SOCS3 (5′-GCCACCTACTGAACCCTCCT-3′ (SEQ ID NO: 23) and 5′-ACGGTCTTCCGACAGAGATG-3′ (SEQ ID NO: 24)), TNFSF10 (5′-TTCACAGTGCTCCTGCAGTC-3′ (SEQ ID NO: 25) and 5′-ACGGAGTTGCCACTTGACTT (SEQ ID NO: 26)), and  TOB1 (5′-GGTGAAAAGGGACCAGTGAA-3′ (SEQ ID NO: 27) and 5′-TGGAGAGCTGGACACTGATG (SEQ ID NO: 28)).

Chromatin Immunoprecipitation (ChIP)

Mock-depleted or VprBP-depleted DU145 cells were grown to 70-80% confluence, cross-linked with 1% formaldehyde for 10 min, and processed for ChIP as recently described (Kim, K. et al. (2012) Mol. Cell Biol. 32:783-796). ChIP assays on B32B2-treated cells were performed in a similar manner, except that DU145 cells were treated with DMSO or 1 μM B32B3 for 24 h. All samples were run in triplicate and results were averaged. Sequences of the primers used for

NOV (promoter, 5′-GCACCAGTGTTGAAGTGTGG-3′ (SEQ ID NO: 29) and  5′-GGCATGCTTGTCATCTCTCA-3′ (SEQ ID NO: 30);  TSS, 5′-GCCCTAAGGAGAGCAGCAC-3′ (SEQ ID NO: 31) and  5′-TTCGCTGTAGATTGGCACTG-3′ (SEQ ID NO: 32);  coding, 5′-CTGCTCATGCTGTCTGGTGT-3′ (SEQ ID NO: 33) and  5′-AGCTGCAGGAGAAGAGGTCA (SEQ ID NO: 34)),  OPN3(promoter, 5′-TAGCTTGCACAAACCCTGTG-3′ (SEQ ID NO: 35) and 5′-TGTGGTTGCACAATCCCTAA-3′ (SEQ ID NO: 36);  TSS, 5′-GAAGGTGCCCAGCCAGTG-3′ (SEQ ID NO: 37) and 5′- GCCTGCTCTAGCCATTGTG-3′ (SEQ ID NO: 38); coding, 5′-CAGGACTCCATTCCTGTGGT-3′(SEQ ID NO: 39) and 5′-GGTTTCGTGCCTTGTTGAGT-3′ (SEQ ID NO: 40)), SOCS2 (promoter, 5′-GAAACGGGGTTGGCTGTAG-3′ (SEQ ID NO: 41) and 5′-GTCGCAATACACAGGCTTCA-3′ (SEQ ID NO: 42); TSS, 5′-ATCCTCGAGGCTTTTGTGTG-3′ (SEQ ID NO: 43) and 5′-TCCCCCGTTAACGTTTAATTT-3′ (SEQ ID NO: 44); coding, 5′-AGGATCTGGGGAGAAAGAGC-3′ (SEQ ID NO: 45) and 5′-GGGTCATGAGAGAAGGGTCA-3′ (SEQ ID NO: 46)), SOCS3 (promoter, 5′- CCGGAAATTCTCTCCTGCTA-3′ (SEQ ID NO: 47) and 5′-GGAGAGCTCGAGGTGGAAC-3′ (SEQ ID NO: 48); TSS,  5′-CTCTCGTCGCGCTTTGTCT-3′ (SEQ ID NO: 49) and 5′-GGAGCAGGGAGTCCAAGTC-3′ (SEQ ID NO: 50); coding, 5′-ATGGTCACCCACAGCAAGTT-3′ (SEQ ID NO: 51) and 5′-GCTGCACATTGGACTCAAAA-3′ (SEQ ID NO: 52)), and TNFSF10 (promoter, 5′-AAAATTAGCTGGGCATGGTG-3′ (SEQ ID NO: 53) and  5′-AACCTCCACCTCCCAGATTC-3′ (SEQ ID NO: 54);  TSS, 5′-GGGACAGTTGCAGGTTCAAT-3′ (SEQ ID NO: 55) and  5′-GGAGCACTGTGAAGATCACG-3′ (SEQ ID NO: 56);  coding, 5′-ATCCAAAGGGACTGGAGCTT-3′ (SEQ ID NO: 57) and 5′- GCTGCACATTGGACTCAAAA-3′ (SEQ ID NO: 58)). quantitative real time PCR (qPCR) are as follows:

B32B3 Stability Assessment

To assess the metabolic stability of B32B3 in mouse, dog, monkey, and human plasma, the compound was spiked into blank plasma to a concentration of 10 μM. At 0, 15, 30, 60, 90, and 120 min time points, a 30 μl aliquot was collected and mixed with 270 μl acetonitrile solution for protein precipitation. After centrifugation, the supernatant was analyzed by LC-MS/MS. In vitro half-life of B32B3 in plasma was calculated using the slope (k) of the log-linear regression from the concentration remaining parent compound versus time.

T _(1/2)=−ln 2/k

Mouse Pharmacokinetics of B32B3

Mouse pharmacokinetic study was carried out using mice (n=5) that were fasted for 12 h prior to and 2 h after dosing with B32B3 (5 mg/kg). Blood samples were collected from orbital sinus at 10, 30, 60, 120, 240, and 480 min post dose. The plasma was separated from blood samples by centrifugation and analyzed in the Agilent 1200 HPLC system coupled to Agilent 6460A QQQ mass spectrophotometer. The plasma concentration-time data were analyzed by noncompartmental analysis using WinNonlin version 4.1 (Pharsight).

It is to be understood that while the invention has been described in conjunction with the above embodiments, that the foregoing description and examples are intended to illustrate and not limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All nucleotide sequences provided herein are presented in the 5′ to 3′ direction.

The inventions illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms “comprising”, “including,” containing”, etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed.

Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification, improvement and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications, improvements and variations are considered to be within the scope of this invention. The materials, methods, and examples provided here are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention.

The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.

TABLE 1 Immunohistochemical staining of VprBP and H2A T120p in tissue microarray of human specimens, related to FIG. 2. VprBP H2A T120p No. Organ Pathology diagnosis Grade Stage staining staining 1 Esophagus Squamous cell carcinoma 3 IIa 3/++ 3/+ 2 Esophagus Squamous cell carcinoma 3 IIa 2/++ 2/+ 3 Esophagus Adenocarcinoma 1 IIa 3/++ 3/++ 4 Esophagus Cancer adjacent normal 0/− 0/− esophagus tissue of No. 1 5 Esophagus Cancer adjacent normal 0/+ 0/+ esophagus tissue 6 Esophagus Cancer adjacent normal 0/+ 0/− esophagus tissue (fibrous tissue and blood vessel) 7 Stomach Adenocarcinoma 3 Ib 1/++ 1/++ 8 Stomach Adenocarcinoma IIIa 1/+ 0/+ 9 Stomach Adenocarcinoma (stomach 2 IV 0/++ 1/++ tissue) 10 Stomach Cancer adjacent normal 0/+ 0/+ stomach tissue 11 Stomach Cancer adjacent normal 0/+ 0/+ stomach tissue 12 Stomach Cancer adjacent normal 0/+ 0/+ stomach tissue of No. 9 13 Colon Adenocarcinoma 2 IIb 0/+ 0/+ 14 Colon Adenocarcinoma 2-3 IIa 2/++ 3/+++ 15 Colon Mucinous Adenocarcinoma 3 III 2/+++ 3/+++ 16 Colon Cancer adjacent normal colon 0/+ 0/+ tissue 17 Colon Cancer adjacent normal colon 0/− 0/+ tissue of No. 15 18 Colon Cancer adjacent normal colon 0/− 1/+ tissue 19 Rectum Adenocarcinoma 1 IIP 0/+ 0/+ 20 Rectum Adenocarcinoma 3 IIP 1/+ 1/+ 21 Rectum Adenocarcinoma 3 III 0/− 0/− 22 Rectum Cancer adjacent normal rectum 0/− 0/− tissue of No. 19 23 Rectum Cancer adjacent normal rectum 0/+ 0/+ tissue of No. 20 24 Rectum Cancer adjacent normal rectum 0/− 0/− tissue of No. 21 25 Liver Hepatocellular carcinoma 2 II 2/++ 2/++ 26 Liver Hepatocellular carcinoma 2 II 2/++ 2/++ 27 Liver Hepatocellular carcinoma 2 II 3/+++ 3/+++ 28 Liver Cancer adjacent normal liver 0/+ 1/+ tissue 29 Liver Cancer adjacent normal liver 1/+ 1/+ tissue 30 Liver Cancer adjacent normal liver 1/+ 1/+ tissue of No. 27 31 Lung Adenocarcinoma 2 II 3/+++ 3/+++ 32 Lung Adenocarcinoma 3 I 3/++ 3/++ 33 Lung Squamous cell carcinoma 3 I 3/++ 3/+++ 34 Lung Cancer adjacent normal lung 0/− 0/− tissue of No. 31 35 Lung Cancer adjacent normal lung 0/− 0/+ tissue 36 Lung Cancer adjacent normal lung 0/− 0/− tissue of No. 33 37 Kidney Clear cell carcinoma 1 II 3/++ 3/++ 38 Kidney Clear cell carcinoma (sparse) I 0/− 0/− 39 Kidney Clear cell carcinoma 1 I 1/+ 2/++ 40 Kidney Cancer adjacent normal kidney 0/− 0/− tissue 41 Kidney Cancer adjacent normal kidney 0/− 0/− tissue of No. 39 42 Kidney Cancer adjacent normal kidney 0/− 0/− tissue 43 Breast Invasive ductal carcinoma 2 IIIb 2/+++ 2/+++ 44 Breast Invasive ductal carcinoma 2 IIb 2/++ 2/++ 45 Breast Invasive ductal carcinoma 2 IIIb 2/++ 2/++ 46 Breast Cancer adjacent normal breast 0/− 0/− tissue (fibrofatty tissue and blood vessel) of No. 43 47 Breast Cancer adjacent normal breast 0/− 0/− tissue of No. 44 48 Breast Cancer adjacent normal breast 0/− 0/+ tissue 49 Uterine Squamous cell carcinoma 1 IIIa 3/+++ 2/++ cervix 50 Uterine Squamous cell carcinoma 2 Ib 2/++ 2/++ cervix 51 Uterine Squamous cell carcinoma 1 Ib 2/++ 3/++ cervix 52 Uterus Cancer adjacent normal uterine 0/+ 0/− cervix tissue 53 Uterus Cancer adjacent normal 0/− 0/− cervical canal tissue 54 Uterus Cancer adjacent normal uterine 0/− 0/+ cervix tissue 55 Ovary Serous adenocarcinoma 3 I 2/+++ 2/++ 56 Ovary Serous papillary 2 Ia 2/++ 3/+++ adenocarcinoma 57 Ovary Serous papillary 2 I 2/++ 2/++ adenocarcinoma 58 Ovary Cancer adjacent normal ovary 0/− 0/+ tissue 59 Ovary Cancer adjacent normal ovary 0/− 0/+ tissue 60 Ovary Cancer adjacent normal ovary 0/+ 0/+ tissue 61 Bladder Transitional cell carcinoma II 1/++ 1/++ (fibrous tissue and blood vessel) 62 Bladder Transitional cell carcinoma 2 II 3/++ 2/++ 63 Bladder Transitional cell carcinoma 3 III 2/+++ 3/+++ 64 Bladder Cancer adjacent normal 0/− 0/+ bladder tissue 65 Bladder Cancer adjacent normal 0/− 0/+ bladder tissue (fibrous tissue and blood vessel) of No. 62 66 Bladder Cancer adjacent normal 0/+ 0/+ bladder tissue 67 Lymph Diffuse B-cell lymphoma of 1/+ 2/++ node left groin 68 Lymph Diffuse B-cell lymphoma of 1/+ 1/+ node right submaxillary 69 Lymph Diffuse B-cell lymphoma of 2/++ 1/+ node left groin 70 Lung Cancer adjacent normal lymph 0/− 1/+ node tissue 71 Cardina Cancer adjacent normal lymph 0/+ 1/+ node tissue 72 Cardina Cancer adjacent normal lymph 1/+ 1/+ node tissue 73 Skin Squamous cell carcinoma 1 II 0/− 0/− 74 Skin Squamous cell carcinoma 2 II 2/+++ 2/+++ 75 Skin Squamous cell carcinoma 3 II 3/++ 2/++ 76 Skin Cancer adjacent normal skin 0/− 0/− tissue (sparse) 77 Skin Cancer adjacent normal skin 0/− 0/− tissue of No. 74 78 Skin Cancer adjacent normal skin 0/− 0/− tissue 79 Cerebrum Astrocytoma (brain tissue) 0/− 0/− 80 Cerebrum Astrocytoma 2 0/+ 1/+ 81 Cerebrum Astrocytoma 2 2/++ 2/++ 82 Cerebrum Cancer adjacent normal brain 0/− 0/− tissue 83 Cerebrum Cancer adjacent normal brain 0/+ 0/+ tissue 84 Cerebrum Cancer adjacent normal brain 0/− 0/− tissue 85 Prostate Adenocarcinoma 1 II 3/+++ 3/+++ 86 Prostate Adenocarcinoma 2 II 2/++ 2/++ 87 Prostate Adenocarcinoma 2-3 IV 2/++ 2/++ 88 Prostate Cancer adjacent normal 0/− 0/+ prostate tissue 89 Prostate Cancer adjacent normal 0/− 0/− prostate tissue 90 Prostate Cancer adjacent normal 0/− 0/− prostate tissue 91 Pancreas Adenocarcinoma 2 I 0/+ 1/+ 92 Pancreas Adenocarcinoma (fibrous I 0/+ 0/+ tissue) 93 Pancreas Adenocarcinoma 3 II 0/+ 0/+ 94 Pancreas Cancer adjacent normal 0/+ 0/+ pancreas tissue 95 Pancreas Cancer adjacent normal 0/+ 0/+ pancreas tissue of No. 92 96 Pancreas Cancer adjacent normal 0/+ 0/+ pancreas tissue

TABLE 2 List of the genes upregulated in VprBP-depleted DU145 cells, related to FIG. 3. Fold Fold Fold Probe ID change Probe ID change Probe ID change LOC100008589 10.95621 SPNS2 2.36224 C14orf138 2.04492 IL11 8.49622 PPP1R15A 2.35618 MEPCE 2.04475 LOC100132564 5.57178 PPIF 2.34898 C1orf182 2.03745 RMRP 5.13069 TMEM156 2.34461 RNU1G2 2.02637 SCARNA18 4.73627 TOB1 2.34228 LOC100134364 2.02278 LOC100008588 4.61836 SNORD3D 2.34112 CIDECP 2.01347 CD24 4.18359 SFXN1 2.33802 NEXN 2.00898 SCARNA11 4.09227 NTN4 2.33693 SLC7A6 2.00493 LOC100133565 3.75485 LOC100132761 2.31059 PCGF6 2.00423 SLC22A18AS 3.6869 SOD2 2.30992 ACYP2 2.00084 Hs.543887 3.53457 DUSP5 2.27879 OPN3 1.9963 KIAA1644 3.46544 INA 2.27157 TJP2 1.99396 MIR1978 3.36967 RNU4ATAC 2.26518 SLC30A1 1.99278 NOV 3.20252 PIGW 2.24255 TRNP1 1.99278 SCARNA14 3.13199 SNORA79 2.24197 PSTK 1.99014 SCARNA8 3.08548 PTGES 2.23998 RNU1-3 1.98478 C6orf48 3.01226 LOC389286 2.22735 DPM2 1.98164 SCARNA16 3.01107 ATF5 2.21293 LOC653610 1.98004 CYP1B1 2.91347 AP1G2 2.20253 VGLL4 1.97867 CYP1A1 2.85512 APITD1 2.19888 PPP3CA 1.97129 BMF 2.84271 LOC645381 2.19595 S100A8 1.96175 TXNIP 2.81931 ITGB2 2.19175 DSTN 1.96022 KCNF1 2.78863 TMEM79 2.17597 ZNF185 1.95996 LOC100132240 2.78373 F3 2.17507 RIOK1 1.95656 UBC 2.75736 PMEPA1 2.15113 MIR1974 1.95551 IGFBP4 2.75471 RNU6ATAC 2.14132 BEND6 1.95473 LPAR1 2.71654 HPCAL1 2.13553 HERC4 1.95369 HIF1A 2.70422 DGCR14 2.12664 C12orf49 1.94948 PPAP2B 2.6787 LOC100132771 2.12214 TNFAIP2 1.94675 AMHR2 2.64693 KLRC3 2.12096 SOCS3 1.94608 RN7SK 2.63914 NCRNA00094 2.10456 DICER1 1.94387 SOCS2 2.62458 ZC3H14 2.10195 RNU1-5 1.94225 SIK1 2.61433 SLPI 2.10091 GEM 1.94147 SYDE1 2.60886 Hs.545589 2.10006 STX1A 1.93722 SCARNA23 2.55733 CCNJL 2.0949 C22orf13 1.93676 MICB 2.49549 C10orf140 2.0934 C1orf86 1.93647 SNORD3A 2.48247 LOC653354 2.08902 SMOX 1.93596 CFL2 2.46382 TNFRSF10D 2.08423 G0S2 1.93484 IL6R 2.44937 C3 2.07775 UCN 1.93312 LOC653879 2.44676 HAS3 2.07037 KGFLP1 1.93078 SNORD3C 2.44287 COX11 2.06194 LOC344887 1.92947 LOC441763 2.43446 ATP6V0E2 2.05825 LOC642118 1.9271 SLAIN1 2.43177 ICMT 2.0546 COTL1 1.92546 RCAN1 2.42618 SUSD2 2.05412 FOXE1 1.92539 RRAD 2.40797 F13A1 2.05061 Hs.575603 1.92446 PPAPDC1A 2.40078 STAG3L4 2.04663 REPIN1 1.92219 C9orf6 1.91099 OXTR 1.81509 RASD1 1.91895 NUP160 1.91023 IDS 1.81451 C19orf33 1.91508 LOC100133511 1.90821 UCRC 1.81374 PDE3B 1.75473 FAM46C 1.8969 RHOD 1.81198 CLCF1 1.75445 PHF14 1.89165 TNRC6B 1.81057 PPARG 1.75354 SH2D4A 1.89006 RAB23 1.81035 MCTP1 1.7522 RAB21 1.88609 ZFAND2A 1.80936 RAB30 1.75208 ST6GALNAC6 1.88472 TGFB2 1.80851 EIF6 1.7516 Hs.565887 1.88382 MORN2 1.80789 TSEN2 1.75139 HSD17B12 1.88248 LOC100130992 1.80648 CD7 1.7475 LOC113386 1.88008 LOC100129828 1.8052 TCF3 1.74646 TAF5L 1.87947 HNRPUL2 1.80508 USP12 1.7454 STIM2 1.87827 KIAA2010 1.80332 AGPAT5 1.74504 RNU6-15 1.87587 SPOCD1 1.80293 BEGAIN 1.74238 KIAA1683 1.87508 RNU4-2 1.8029 LOC728640 1.74212 TCTA 1.8746 BCL7B 1.79941 ODF2 1.74148 GPR137B 1.87293 FGF2 1.7985 MED1 1.74124 MPDU1 1.86958 CASD1 1.79472 HMOX1 1.73955 RNF7 1.86801 REEP3 1.79401 LOC645676 1.73679 CLDN15 1.86474 RCL1 1.78888 LOC339804 1.73625 RNU6-1 1.86224 HBEGF 1.78832 NKX3-1 1.73619 RNU1A3 1.86106 ZCWPW1 1.78801 TGM2 1.73592 ZC3H8 1.85225 CGGBP1 1.78799 MIB2 1.73494 PPARBP 1.85133 BRPF3 1.78795 HIST1H2BK 1.73493 KYNU 1.84888 GLCCI1 1.78469 Hs.556082 1.73316 AKIRIN1 1.84823 TOMM34 1.78467 ODC1 1.73164 MAPKAPK2 1.84637 BTBD7 1.78078 CCNYL1 1.73042 SMG7 1.84559 S100A13 1.77958 GTF2IRD2B 1.73017 RNY1 1.84555 FBXW2 1.77898 C21orf2 1.72741 Hs.534061 1.84254 PINK1 1.77891 Hs.568329 1.72736 DLK2 1.8403 RPL34 1.77762 DDX10 1.72735 TNFSF10 1.83912 TRIM44 1.77663 LGR4 1.72658 F8A1 1.83828 DYRK3 1.77298 OBFC2A 1.72458 SCML2 1.83782 DYSF 1.77256 KCMF1 1.72451 ISCA1 1.8371 IGF2BP3 1.77216 GPX1 1.72445 LOC401233 1.83563 CHN1 1.7721 BAD 1.72434 DNAJC25 1.8356 DPP9 1.76985 RNY4 1.72133 Hs.91389 1.83318 ARPC1A 1.76981 USP22 1.72014 GBP1 1.83181 CBLL1 1.76954 ZNHIT6 1.71805 KIAA1666 1.83127 PVT1 1.7684 LOC653450 1.71697 PPL 1.82944 PEF1 1.76753 IL1RL1 1.71563 LOC402617 1.82572 TMEM217 1.76675 Hs.540724 1.7147 SPNS2 1.82448 C6orf66 1.76323 KLK3 1.71446 KLF10 1.82281 H2AFY 1.76152 TMEM180 1.71051 FAM168B 1.82222 C9orf169 1.76142 HRB 1.70994 GLRX2 1.82176 LAT 1.76057 LOC387763 1.70986 LOC441481 1.82061 MAX 1.75785 C19orf48 1.70956 CPM 1.81512 CTRL 1.75487 AGFG1 1.70904 IL4R 1.70707 C1GALT1 1.70454 OAZ2 1.70851 REV3L 1.70646 RBKS 1.70249 ZNF219 1.70716 WNT7A 1.70604 LOC727945 1.70176 RNU4-1 1.70594 SCARNA20 1.70017

TABLE 3 List of the genes downregulated in VprBP-depleted DU145 cells, related to FIG. 3. Probe ID Fold change Probe ID Fold change Probe ID Fold change SNORD13 −4.76013 STMN3 −2.69955 VTA1 −2.36258 CYP24A1 −4.69112 HOMER2 −2.69622 PFKL −2.35716 RASL10A −4.50653 VPRBP −2.69554 CA2 −2.35239 CCL20 −4.33102 FBXO4 −2.66715 SEPT5 −2.3515 IGFBP3 −4.12725 ADAM23 −2.66614 CBS −2.32465 LCN2 −3.99251 HLA-DOB −2.64214 DDIT4 −2.31864 SRPX −3.89196 PTPRE −2.63881 RIMS3 −2.31602 SYTL2 −3.72792 DDAH1 −2.62998 GNG4 −2.31208 ERLIN2 −3.708 SELM −2.61246 B4GALNT1 −2.31172 SPP1 −3.64917 CFD −2.61173 NMD3 −2.30645 OPLAH −3.56388 LOC730415 −2.60748 KCNQ2 −2.30063 TMEM145 −3.55171 MCOLN2 −2.60564 ECHDC3 −2.29554 HLA-DMA −3.54901 NICN1 −2.59474 MOSPD3 −2.29472 PCK2 −3.39215 SCNN1A −2.57872 AIF1L −2.29356 ANG −3.3747 CYP4F11 −2.56978 CRIP1 −2.28066 RNASE4 −3.34991 EFHD1 −2.56425 HSPA5 −2.26752 KIF1B −3.2912 DPYSL4 −2.54773 LTBP4 −2.26681 GALNTL1 −3.2398 RBP1 −2.54231 F12 −2.26624 ACCN2 −3.23115 WFDC3 −2.52798 KCNK15 −2.26529 MAP1LC3A −3.09754 STAT4 −2.51561 RDH10 −2.24289 LAMP3 −3.06117 BBS7 −2.51497 LEPREL2 −2.24037 KISS1R −3.01598 CBLC −2.51361 PAQR8 −2.23745 DDIT4L −3.00965 CDC42EP5 −2.50702 TUBB2B −2.2258 CLYBL −3.00486 EPHX2 −2.50536 CLDN7 −2.22503 H1FX −2.9432 NUDT18 −2.49831 SEZ6L2 −2.22419 PRPH −2.94106 PGM2L1 −2.48024 HLA-DRB1 −2.22167 GLO1 −2.94083 ULBP1 −2.47582 MXRA7 −2.21861 EGR1 −2.93183 ELOVL4 −2.46244 CYP26B1 −2.21718 PRODH −2.90908 ASNS −2.46226 OXCT1 −2.21436 TMEM107 −2.88271 CMTM4 −2.45959 PLOD1 −2.20886 TMSB15A −2.86058 AHCTF1 −2.45763 TMEM45A −2.20746 FLJ20444 −2.8544 MAP4K1 −2.45566 SNX10 −2.2021 UPK1A −2.8322 FXYD6 −2.44858 S100A4 −2.19894 STS-1 −2.82727 TM7SF2 −2.43709 PIGZ −2.19516 LRRN2 −2.80333 COL6A1 −2.43078 WISP2 −2.193 PDIA4 −2.79743 MTX2 −2.41788 GNG7 −2.18561 GALC −2.77678 UBASH3B −2.40128 HSPB8 −2.15889 FUCA1 −2.75977 GOLSYN −2.39573 OSGIN2 −2.15606 TSTD1 −2.74491 H1F0 −2.39163 SLC2A3 −2.15503 CXorf61 −2.73964 MAPT −2.38724 MLLT11 −2.1339 RAB26 −2.73737 DHRS3 −2.37749 GNAI3 −2.13342 FGFBP1 −2.73291 MPZL2 −2.37523 CUGBP2 −2.13211 MGC39900 −2.72135 GXYLT1 −2.3664 JAZF1 −2.1315 HLA-DPA1 −2.71792 SGK −2.36494 ABHD1 −2.12012 CYP26A1 −2.70874 PARM1 −2.36369 SIRT4 −2.11814 SLC24A6 −2.70779 GRHPR −2.36322 N4BP1 −2.11786 CERCAM −2.10843 BDNF −1.79092 ROR1 −2.11773 FAM84B −2.10647 MAOA −1.79078 RDM1 −2.1113 ESPL1 −2.01313 DECR1 −1.73255 ZFC3H1 −1.85227 RPRML −2.00454 FKBP5 −1.73199 IDH1 −1.85147 NSL1 −2.00364 LRRC45 −1.73121 GJB2 −1.84965 SH3BGRL2 −2.00204 NRG4 −1.73096 ECM1 −1.82754 NDRG1 −2.00143 PYCR1 −1.73012 CRELD2 −1.8274 HES7 −2.00073 PQLC3 −1.72937 PLCG2 −1.82466 FEZ1 −1.99933 NES −1.71073 DNAJC4 −1.79501 FLJ22536 −1.99034 CYP4V2 −1.70899 CACNA2D2 −1.79385 MKRN1 −1.99011 TFPI −1.70884 RBP7 −1.79384 CHST13 −1.95803 WFDC2 −1.70331 CEP70 −1.79346 CENTA1 −1.95223 PRSS12 −1.70275 ACSM3 −1.79277 CXCL2 −1.93765 MAPK3 −1.70214 CTSH −1.79174 STRADB −1.9103 MOCOS −1.7021 CNTN1 −1.86233 NCAPG2 −1.91024 PPFIA4 −1.70174 SSH3 −1.86181 FBXO2 −1.90867 KDELR3 −1.70166 TCIRG1 −1.86102 RPS6KA5 −1.90636 RALBP1 −1.70153 CIB2 −1.86029 PKD2 −1.90543 ASNSD1 −1.7009 GLT25D2 −1.85831 SLC35C1 −1.90514 CXCL1 −1.70045 EFEMP2 −1.85527 ID2 −1.90325 ASNSD1 −1.7009 PALM −1.85364 NRBP2 −1.90295 CXCL1 −1.70045 MXD3 −1.85281 ZWILCH −1.89623 CHST6 −1.89448 HMGCL −1.88948 FGFR3 −1.89613 THBS3 −1.89045 XPR1 −1.88925

TABLE 4 Inhibition of human kinases by B32B3, related to FIG. 4. Kinase IC₅₀ (μM) Kinase IC₅₀ (μM) VprBP 0.6 DNAPK >10 AKT1 >10 DYRK1 >10 AKT3 >10 EEF2K >10 ATM >10 GSK3β >10 ATR >10 HCK >10 AURKA >10 LCK >10 AURKB >10 PKM2 >10 BCK >10 PKN2 >10 BUB1 >10 PRKCD >10 CDK2 >10 PLK1 >10 CDK7 >10 PLK2 >10 CDK9 >10 RSK2 8.6 CDK18 >10 RSK3 >10 CHK1 >10 STK25 >10 CHK2 >10 STK33 >10 CSNK1D >10 SYK >10 CSK1E >10 VRK2 >10 

What is claimed is:
 1. A method for on or more of: a. inhibiting the growth of a cancer cell; b. activating tumor suppressor function in a cell comprising functional tumor suppressor genes; and c. inhibiting H2AT120P in a cell comprising functional H2AT120P, comprising contacting the cell with an effective amount of an agent that inhibits VprBP kinase activity in the cell, wherein the agent is the composition of claim 3 or
 4. 2. A method for inhibiting the growth of a cancer cell in a patient or treating cancer in a patient, comprising administering to the patient in need thereof an effective amount of the composition of claim 3 or
 4. 3. A composition comprising a carrier and a VprBR kinase-specific RNAi.
 4. The composition of claim 3, wherein VprBR kinase-specific RNAi is selected from the group of reference polynucleotides of consisting of VprBP shRNA1 (SEQ ID NO: 1: 5′-CGAGAAACTGAGTCAAATGAA-3′), VprBP shRNA2 (SEQ ID NO: 2: 5′-AATCACAGAGTATCTTAGA-3′) and Bub1 shRNA (SEQ ID NO: 3:5′-CGAGGTTAATCCAGCACGTAT-3′), or an equivalent thereof, wherein an equivalent of each thereof, wherein an equivalent thereof comprises a polynucleotide that has at least 80% sequence identity to the reference polynucleotide and inhibits VprBP kinase activity or a polynucleotide that hybridizes under conditions of high stringency to the reference polynucleotide or its complement, wherein conditions of high stringency comprise hybridization reaction at about 60° C. in about 1×SSC and inhibits VprBP kinase activity.
 5. The composition of claim 3, wherein the carrier is a pharmaceutically acceptable carrier or an in situ device.
 6. The composition of claim 5, wherein the device is a catheter. 